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ABSTRACT 
The major bacterial species that cause respiratory tract infections, 
Streptococcus pneumoniae, Haemophilus influenzae and Moraxella 
catarrhalis have been moderately susceptible to different antimicrobial 
agents in Finland, but various studies have shown that their resistance to 
antimicrobials is growing. Consumption of antimicrobial agents has been 
shown to associate positively with the development of resistance. This study 
examined resistance to antimicrobial agents in the above-mentioned 
bacterial species from the perspective of methodological issues and 
antimicrobial consumption.  
 
Material and Methods: Reference isolates were used to find the most 
appropriate susceptibility testing method for H. influenzae, particularly to 
identify the non-β-lactamase mediated ampicillin-resistance (β-lactamase 
negative ampicillin resistant, BLNAR). Twenty-six Finnish clinical 
microbiology laboratories participated in this study. 
Quality control results (2004–2006) from 21 Finnish laboratories were 
collected to analyze the accuracy of their susceptibility testing practices for 
H. influenzae and S. pneumoniae. The results were compared to the expected 
values provided by the standard (FiRe, Finnish Study Group for 
Antimicrobial Resistance) applied in Finland at that time.  
Performance of an automated susceptibility testing method for S. 
pneumoniae (Vitek2® AST-GP74) was investigated using 229 isolates that 
had been obtained from Päijät-Häme Central Hospital (Lahti, Finland). The 
broth dilution method (Sensititre®) was used as the reference method. 
Breakpoints provided by the European Committee for Antimicrobial 
Susceptibility Testing (EUCAST) were used for evaluating the results.  
Macrolide resistance mechanisms among H. influenzae strains from three 
periods (1988–1991, n=204; 1999–2000, n=379 and 2006–2011, n=130) 
were examined. Ribosomal methylation, active efflux and mutations in the 
bacterial ribosome in positions critical for macrolide binding were 
investigated.  
The effect of sulfamethoxazole-trimethoprim consumption on the 
resistance levels of these three respiratory pathogens was examined by 
comparing regional resistance (1997–2003; FINRES) by hospital districts 
(n=21), with the respective drug use for the preceding year expressed as the 
defined daily doses (DDD)/1000 inhabitants/day; Finnish Medicines 
Agency, Fimea). The associations were modeled using a linear mixed model 
with drug use as the explanatory factor and resistance (%) as the dependent 
variable. 
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Results: BLNAR H. influenzae strains were detected better by using the low 
concentration disks of ampicillin (2 μg, sensitivity 92%, specificity 90%) and 
of amoxicillin-clavulanic acid (3 μg, sensitivity 92%, specificity 90%) than by 
using the high concentration disks (10 μg and 30 μg, sensitivities 71% and 
44%, specificities 88% and 96%). This was also noted in the study, which 
examined the quality control results. 22.8% (n=372) and 78.9% (n=218) 
results were found to be incorrect when the high strength-disks were used. 
The corresponding figures for low concentration discs were 1.5% (n=596) 
and 4.5% (n=484).  
An automatic susceptibility testing method (Vitek2®, AST GP74) provided 
highly comparable results for S. pneumoniae with the broth dilution method. 
Categorical agreement (CA) was 95.2–100% depending on the drug. The total 
number of false susceptible results (FS) was 1.0%, minor errors (mE) 1.3%, 
major errors (ME) 0.1% and very major errors (VME) 1.6%. Overall essential 
agreement was (EA) 99.0%. The EUCAST -guidelines for susceptibility 
testing provides different breakpoints for penicillin and meropenem, when 
meningitis isolates are examined. Results of this automated method showed 
2.6% very major errors in the interpretation of penicillin-results and 0.4% 
minor errors in meropenem-results with the meningitis breakpoints. These 
results must therefore be interpreted with caution, when the isolate has been 
obtained from cerebrospinal fluid.  
Macrolide resistance among Finnish H. influenzae strains is very low 
(n=6/713, 0.8% of the total material). Among the resistant strains no mobile 
resistance genes (erm, mef) were detected. These genes are common in 
macrolide-resistant pneumococci. Mutations associated with resistance to 
macrolide resistance reported in other bacterial species were found. Five 
(5/6) resistant strains carried mutations in ribosomal proteins L4 (T64K) 
and L22 (E78D, DEL79GP), and in the ribosome (23S rRNA, A2058G). The 
only L22–mutation observed in this study has not been described previously.  
Regional sulfamethoxazole-trimethoprim consumption was found to have 
a positive connection with resistance in S. pneumoniae (p=0.007) but the 
change of resistance was not significant (p=0.452). The change in resistance 
over time for H. influenzae was border-line significant (p=0.051), but the 
drug use did not explain the trend (p=0.808). The change in resistance 
among M. catarrhalis was not statistically significant (p=0.349) and there 
was no significant association (p=0.744) between the drug consumption and 
the level of resistance. The use of sulfamethoxazole-trimethoprim fell 
throughout the country during the investigation period. 
 
Conclusions: The accuracy of the susceptibility testing of bacteria requires 
evidence-based standardization and continuous quality controlling.  Clinical 
laboratory automation can be implemented safely in pneumococcal 
susceptibility testing. Increasing use of macrolide antibiotics towards the end 
of the 20th century has hitherto not produced significant resistance in H. 
influenzae in Finland. The impact of sulfamethoxazole-trimethoprim 
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consumption on resistance varies for different bacterial species. A reduction 
in its use in the long run has not led to a significant reduction in resistance.  
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TIIVISTELMÄ 
Tärkeimmät hengitystieinfektioita aiheuttavat bakteerit Streptococcus 
pneumoniae, Haemophilus influenzae ja Moraxella catarrhalis ovat olleet 
Suomessa kohtalaisen herkkiä mikrobilääkkeille, mutta eri tutkimuksissa on 
myös todettu, että resistenssi on kasvusuunnassa. Mikrobilääkkeiden 
kulutuksella on osoitettu olevan yhteys resistenssin kehittymiseen. Tässä 
tutkimuksessa on tarkasteltu hengitystiepatogeenien resistenssiä 
menetelmänäkökulmasta sekä tutkittu lääkekulutuksen yhteyttä resistenssin 
kehittymiseen.  
 
Aineisto ja menetelmät: Resistenssiltään tunnettuja H. influenzae 
kantoja käytettiin tutkimuksessa, jossa haettiin soveltuvinta menetelmää 
erityisesti β-laktamaasi negatiivisten, ampisilliiniresistenttien (BLNAR) 
kantojen löytämiseksi. Kyseessä oli suomalaisissa kliinisen mikrobiologian 
laboratorioissa (n=26) suoritettu monikeskustutkimus.  
Suomalaisten laboratorioiden (n=21) herkkyysmääritystulosten 
oikeellisuutta selvitettiin keräämällä suositusten mukaisten 
vertailubakteerikantojen (H. influenzae ja S. pneumoniae) tulokset kolmen 
vuoden ajalta (2004 – 2006). Tuloksia verrattiin tuona ajankohtana 
Suomessa käytössä olleen herkkyysmääritysstandardin (Finnish Study Group 
for Antimicrobial resistance, FiRe) antamiin suositusarvoihin.  
Automaattista menetelmää (Vitek2®, AST GP74) S. pneumoniaen 
herkkyysmäärityksissä tutkittiin Päijät-Hämeen keskussairaalassa 
eristettyjen potilaskantojen (n=229) avulla. Vertailumenetelmänä käytettiin 
liemilaimennosmenetelmää (Sensititre®).  
H. influenzae–kantojen makrolidiresistenssin mekanismia selvitettiin 
kolmesta noin 10 vuoden välein suomalaisissa laboratorioissa kerätystä 
bakteerikantakokoelmasta (1988–1991 n = 204; 1999–2000 n = 379 ja 
2006–2011 n = 130). Kannoista tutkittiin geenit, jotka johtavat ribosomien 
metylaatioon ja lääkkeen pumppaamiseen ulos solusta sekä lääkkeiden 
sitoutumiskohtaan liittyvät mutaatiot ribosomeissa.  
Sulfa-trimetopriimin käytön vaikutusta kolmen hengitystiepatogeenin 
resistenssiin tutkittiin vertaamalla sairaanhoitopiireittäin (n=21) alueellista 
resistenssiä (1997–2003, FINRES) edellisen vuoden lääkekäyttöön 
(DDD/1000 asukasta/päivä, Finnish Medicines Agency, Fimea). Yhteyttä 
mallinnettiin tilastollisesti käyttämällä lineaarista sekamallia, jossa 
lääkekäyttö oli selittävänä tekijänä ja resistenssi (%) riippuvana muuttujana.  
 
Tulokset: BLNAR H. influenzae – kannat todettiin laboratorio-olosuhteissa 
kiekkoherkkyysmenetelmällä selvästi paremmin käyttäen matalan 
pitoisuuden ampisilliini (2 μg, herkkyys 92 %, spesifisyys 90 %) ja 
amoksasilliini-klavulaanihappokiekkoja (3 μg, herkkyys 92 %, spesifisyys 90 
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%) kuin käyttämällä korkean pitoisuuden kiekkoja (10 μg ja 30 μg, herkkyys 
71 % ja 44 %, spesifisyys 88 % ja 96 %). Tämä todettiin myös tutkimuksessa, 
jossa selvitettiin vertailukantojen tulosten osuvuutta. 22.8 % (n=372) ja 78.9 
% (n=218) mittaustuloksista johti virheelliseen herkkyysluokitukseen 
korkean pitoisuuden kiekoilla. Vastaavat luvut matalan pitoisuuden kiekoilla 
olivat 1.5 % (n=596) ja 4.5 % (n=484).  
Automaattinen herkkyysmääritysmenetelmä (Vitek2®, AST-GP74) tuottaa 
vertailukelpoisia tuloksia S. pneumoniaen herkkyysmäärityksissä verrattuna 
referenssimenetelmään. Tulkintatulos (S/I/R) oli yhtäpitävä 95.2 – 100 % 
mittauksista lääkeaineesta riippuen. Vääriä S -tuloksia todettiin 
kokonaisuudessaan 1.1 %, vähäisiä virhetulkintoja 1.3 %, merkitseviä 
virhetulkintoja 0.1 % ja vakavia virhetulkintoja 1.6 %. EUCAST – 
herkkyysmääritysstandardissa selkäydinnestenäytteistä eristetyille S. 
pneumoniae -kannoille on suositeltu penisilliinille ja meropeneemille 
erilaisia luokittelurajoja kuin muille näytteille. Automaattimenetelmällä 
näitä tulkintarajoja käyttäen todettiin 2.6 % vakavaa poikkeamaa 
penisilliinin ja 0.4 % vähäistä poikkeamaa meropeneemin tuloksissa.  
Suomalaisten H. influenzae -kantojen makrolidiresistenssi on hyvin 
matalaa (6/713, 0.8 % koko aineistossa). Resistenteissä kannoissa ei todettu 
siirtyviä resistenssigeenejä (erm, mef), jotka ovat tyypillisiä mm. 
makrolideille resistenteillä pneumokokkikannoilla. Tässä työssä yhdellä 
resistentillä kannalla ei havaittu makrolidiresistensiin liittyviä tunnettuja 
mutaatioita. Viidellä (5/6) resistenteistä kannoista havaittiin mutaatioita 
ribosomaalisissa proteiineissa L4 (T64K) ja L22 (E78D, DEL79GP) sekä 
ribosomissa (23SrRNA, A2058G). L22–proteiinissa havaittua mutaatiota ei 
ole kuvattu aiemmin.  
Alueellisella sulfa-trimetopriimin kulutuksella havaittiin olevan 
positiivinen yhteys myöhempään resistenssiin S. pneumoniae-lajilla 
(p=0.007), mutta resistenssin muutos tutkimusajanjaksolla ei ollut 
merkitsevää (p=0.452). H. influenzae-lajilla resistenssin muutos tällä 
ajanjaksolla oli tilastolliselta merkitsevyydeltään raja-arvoinen (p=0.051), 
mutta lääkekäyttö ei selittänyt resistenssin muutosta (p=0.808). M. 
catarrhalis–kannoilla ei havaittu tilastollisesti merkitsevää muutosta 
resistenssissä (p=0.349) eikä lääkekäytön ja resistenssin välillä todettu 
yhteyttä (p=0.744). Sulfa-trimetopriimin kulutus väheni koko maassa 
tutkimusajankohtana.  
 
Johtopäätökset: Bakteereiden herkkyysmääritystulosten oikeellisuus 
edellyttää näyttöön perustuvaa standardointia ja herkkyysmääritysten 
tulostasojen seuranta tulee sisällyttää laboratorion toimintaan. Kliinisen 
laboratorion automaatiota voidaan edistää turvallisesti pneumokokin 
herkkyysmäärityksen osalta. Makrolidiantibioottien kasvava käyttö 1900 – 
luvun lopulla ei ole toistaiseksi tuottanut merkittävää resistenssiä H. 
influenzae – kantoihin. Sulfaftrimetopriimin käytön vaikutus resistenssiin on 
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erilaista eri bakteerilajien kohdalla. Sen käytön väheneminen ei pitkällä 
aikavälillä ole johtanut merkittävään resistenssin vähenemiseen. 
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Testing 
Fimea Finnish Medicines Agency 
 19 
FiRe 
FS 
Finnish Study Group for Antimicrobial resistance 
false susceptible 
FSR false susceptibility rate 
GTP guanosine triphosphate 
HTM Haemophilus Test Medium 
I intermediate 
IS Iso Sensitest 
IQA internal quality assessment 
MALDI-TOF MS matrix-assisted laser desorption ionization-time of flight  
mass spectrometry  
mE minor error 
ME major error 
MEF middle ear fluid 
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MH-F 
Muller-Hinton agar/medium 
Muller-Hinton agar for fastidious bacteria 
MIC minimal inhibitory concentration 
mRNA messenger ribonucleic acid (messenger RNA) 
MRSA methicillin resistant Staphylococcus aureus 
NCCLS National Committee for Clinical laboratory Standards 
NGS next generation sequencing 
NT non-typable 
OM outer membrane 
Oxa oxacillin 
PBP penicillin binding protein 
PCR polymerase chain reaction 
PDD prescribed daily doses 
Pen penicillin 
PROTEKT Prospective Resistant Organism Tracking and 
Epidemiology for the Ketolide Telithromycin 
qc quality control 
R resistant 
ROB ß-lactamase, named after a patient 
rRNA ribosomal ribonucleic acid (ribosomal RNA) 
RTI  respiratory tract infection 
S susceptible 
SD standard deviation 
SFM Comite de l’Antibiogramme de la Societe Francaise de 
Microbiologie  
SRGA Swedish Reference Group for Antibiotics 
SxT sulfamethoxazole-trimethoprim 
Tcy tetracycline 
TEM ß-lactamase, named after the patient  
THFA tetrahydrofolic acid 
Tlt telithromycin 
Tmp trimethoprim 
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tRNA transfer ribonucleic acid (transfer RNA) 
TTR time to results 
UKNEQAS United Kingdom National External Quality Assessment 
Services 
URTI upper respiratory tract infection 
Van vancomycin 
VGS viridans group streptococci 
VISA vancomycin intermediate Staphylococcus aureus 
VSSA vancomycin susceptible Staphylococcus aureus 
WGS  whole genome sequencing 
VME very major error 
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1 INTRODUCTION 
Increasing trend of antimicrobial resistance in bacteria that cause infectious 
diseases is a global problem, although resistance significantly varies between 
geographical regions. Today, common bacterial pathogens can be resistant to 
all known antimicrobial agents (Mediavilla et al., 2016; Skov and Monnet, 
2016). The growing resistance has been linked to the increasing use of 
antimicrobials in humans (Bergman et al., 2006).  Nontherapeutic use of 
antibiotics in food industry and antimicrobial use in veterinary medicine add 
the reservoir of resistant bacteria in animals. There is evidence that such 
resistant isolates have transfered from animals to humans (Marshall et al., 
2011).  
The battle against antimicrobial resistance is highly dependent on the 
knowledge of resistance rates for different bacterial species and also requires 
accurate methods to measure resistance. In Finland laboratories provide 
resistance data for the national FINRES report on annual basis. These annual 
resistance data have already accumulated and have been archieved for a long 
period with high coverage. Finnish laboratories are also committed to using 
standardised susceptibility testing methods, which is expected to guarantee 
the quality and uniformity of the national resistance data. Methodological 
harmonization has proceeded lately even at the European level, therefore we 
can expect to get access to internationally comparable resistance data. 
Respiratory tract infections (RTI) are the most common reason to 
prescribe antibiotics in the Finnish primary health care sector (Rautakorpi et 
al., 2001). Of the main respiratory pathogens, Streptococcus pneumoniae 
and its resistance to macrolides has been most studied in Finland. Latest 
studies of other respiratory pathogens date back to the 1990s.  
This research aimed to complement the Finnish susceptibility standard, 
determine the quality of Finnish resistance data, examine the association 
between the use of sulfamethoxazole-trimethoprim and resistance in three 
major bacterial respiratory pathogens, and investigate the level and 
mechanisms of macrolide resistance in H. influenzae. These studies can 
promote the quality of Finnish resistance data among respiratory pathogens 
and shed some light on the difficult issue of the mechanism(s) between 
antimicrobial use and resistance.  
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2 REVIEW OF THE LITERATURE 
2.1 The bacteria that cause upper respiratory tract 
infections 
2.1.1 Major pathogens 
2.1.1.1 Streptococcus pneumoniae  
The taxonomic classification of the streptococci is presented in Table 1. 
Table 1. Taxonomy of Streptococcus pneumoniae (De Vos et al., 2009). 
Kingdom Bacteria 
Phylum Firmicutes (low G+C content gram-positive bacteria) 
Class Bacilli 
Order Lactobacillales 
Family Streptococcaceae 
Genus Streptococcus 
Species Streptococcus pneumoniae 
 
Bacterial species included in the genus Streptococci are catalase-negative, 
gram-positive cocci that form chains and pairs especially when grown in 
liquid media. The phenotypic classification of the genus Streptococci, still 
considered of value in clinical microbiology, separates the group into ß–
haemolytic streptococci (also called pyogenic streptococci) and non-pyogenic 
streptococci. The non-pyogenic (also referred to as viridans streptococci) 
group includes over 30 α–haemolytic, non-haemolytic and even some ß–
haemolytic species and is further divided into five groups on the basis of 16S 
rRNA gene sequencing. These five groups are: S. mitis, S. anginosus, S. 
mutans, S. salivarius and S. bovis. S. pneumoniae is α–haemolytic and is 
clustered genetically in the mitis group (Kawamura et al., 1995; Spellerberg 
and Brandt, 2015).  
S. pneumoniae was first described in the late 1880s, in France as Microbe 
septichemique du salive and concurrently in the U.S.A. as Micrococcus 
pasteuri. When the organism was recognized to be the most common cause 
of pneumonia, it was termed as “pneumococcus”, but later named as 
Diplococcus pneumoniae because of its typical dyadic appearance under the 
microscope, and then finally in 1974 it was again renamed as S. pneumoniae 
(Musher, 2009). 
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S. pneumoniae is easily distinguished from other viridans-group 
streptococci on the basis of its colonial morphology. The colonies are 
greenish on blood agar and chocolate agar media (due to partial haemolysis), 
often mucoid due to the production of capsular polysaccharides and have a 
characteristic central depression, which is a result from the production of 
pneumococcal autolysin. In addition to the typical morphology, the basic 
methods in clinical microbiology laboratories to identify pneumococci are 1) 
optochin susceptibility and 2) bile solubility (Spellerberg and Brandt, 2015; 
Musher, 2009). Not all pneumococci are susceptible to optochin (Munoz et 
al., 1990; Kaijalainen et al., 2002). On the other hand, a recently described 
species, S. pseudopneumoniae is susceptible to optochin when grown in 
ambient air (Keith et al., 2006). The bile solubility tests identify S. 
pneumonie with 99–100% sensitivity and 98–99% specificity (Kellogg et al., 
2001). In recent years, the matrix-assisted laser desorption ionization-time 
of flight mass spectrometry (MALDI-TOF-MS) technique has emerged as an 
alternative for the identification of a wide range of bacteria, mycobacteria 
and fungi. The identification is based on the protein composition of the 
microbial cell. The ability of MALDI-TOF-MS methods to identify S. 
pneumonia correctly is highly dependent on the platform used (Neville et al., 
2011; deBel et al., 2010; Dubois et al., 2013; Branda et al., 2013; Kärpänoja et 
al., 2014; Harju et al., 2017).  
S. pneumoniae colonizes the nasopharynx of healthy adults and children. 
Pneumococci are cultured from the upper airways in 5% to 10% of healthy 
adults and 20% to 40% of healthy children. The carriage rate has seasonal 
variation (highest in midwinter) and also population–based variation (ethnic 
and socio-economic differences). Pneumococci spread directly from a 
colonized person and cause infections like sinusitis and bronchitis in the 
respiratory tract and infections in the adjacent organs, e.g. otitis media. 
Haematogenous spreading may result in meningitis, pneumonia, primary 
bacteremia and other invasive infections (Musher, 2009). S. pneumoniae is 
among the most prevalent species that is cultured from middle ear fluids of 
children with acute otitis media and from patients with acute sinusitis (Wald, 
2011; Ngo et al., 2016).  
S. pneumoniae strains possess several virulence factors, of which the 
capsular polysaccharide is by far the most important. Antigenic differences in 
the capsule result in approximately 90 serotypes. A meta-analysis by 
Brueggeman and colleagues (2004) showed that pneumococcal serotypes 
and serogroups differ in invasiveness: serotypes 1, 5 and 7 were 60-fold more 
invasive than serotypes 3, 6A and 15.  After introduction of the 7-valent and 
later the 13-valent pneumococcal vaccines in France, S. pneumoniae 
infections decreased in all age groups. The decrease was significant in 
invasive infections and in respiratory tract infections (Abat et al., 2015).  
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2.1.1.2 Haemophilus influenzae 
Haemophilus influenzae belongs to the phylum Proteobacteria (Table 2).  
 
Table 2.Taxonomy of Haemophilus influenzae (Brenner et al., 2005). 
Kingdom Bacteria 
Phylum Proteobacteria 
Class Gammaproteobacteria 
Order Pasteurellales 
Family Pasteurellaceae 
Genus Haemophilus 
Species Haemophilus influenzae 
 
 
The genus Haemophilus comprises eight bacterial species, which are 
associated with humans (H. influenzae, H. aegyptius, H. ducreyi, H. 
pittmanniae, H. parainfluenzae, H. haemolyticus, H. parahaemolyticus, 
and H. paraprohaemolyticus). They are gram-negative bacteria and the 
morphology ranges from small coccobacillary forms to filamentous rods. All 
species are facultative anaerobes. Nowadays, the genus is limited to human-
associated species and no other natural hosts are known. The species of 
animal origin have been transferred to the genus Pasteurella  (Ledeboer and 
Doern, 2015; Murphy 2009 a).  
The genus name Haemophilus (blood-loving) refers to the characteristic 
that aerobic growth of bacteria in this genus requires two substances named 
as either X-factor or V-factor or both of them. X-factor is protoporphyrin IX, 
a metabolite in haemin biosynthesis. V-factor is a coenzyme composed of 
nicotinamide compounds (NAD or NADP) (Ledeboer and Doern, 2015).  
To isolate Haemophilus species from clinical specimens, special attention 
has to be paid to the media used. Depending on the species, the medium has 
to provide the X-factor and/or V-factor. The X-factor is easily available for 
bacteria on traditional blood agar, but in order to release the V-factor, the 
blood cells have to be lysed (to prepare “chocolate–agar”). This factor can 
also be provided for the bacteria by cross-streaking Staphylococcus aureus 
or enterococci onto blood agar. S. aureus bacteria produce the V-factor and 
thus allow the growth of all Haemophilus species even on a common blood 
agar plate (satellite growth). Selective antibiotics such as bacitracin can be 
utilized to cultivate Haemophilus species from mixed flora of respiratory 
tract specimens (Ledeboer and Doern, 2015). 
The first reports of H. influenzae were published by the German 
microbiologist Richard Pfeiffer in the 1890s (von Graevenitz, 2008). At that 
time it was claimed to be the agent that caused epidemic influenza. This 
theory turned out to be false. H. influenzae is the main species associated 
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with infections for the genus. Only one species, H. ducreyi (the causative 
agent of chancroid), is a primary pathogen, whereas all other species may be 
commensal as well (Ledeboer and Doern, 2015; Murphy 2009 a). H. 
influenzae was the first microbial agent apart from viruses, whose entire 
genome was sequenced (H. influenzae Rd; Fleischman et al., 1995).  
Colonies of H. influenzae on chocolate agar are small (1–2 mm diameter), 
brownish, flat, smooth and semi opaque. Strains possessing a polysaccharide 
capsule are often mucoid. The species level identification is based on the 
typical colony morphology, a characteristic smell of growth (“mouse-nest 
smell”) and testing the growth factor requirements. A number of methods 
can be applied for the “factor” test: satellite growth-test to test V-factor 
dependency, paper-disk-test for X-dependent and V-dependent species and 
the porphyrin test for X-factor requirement. Four species induce haemolysis 
on bovine, horse or rabbit agar plates. The factor requirements and 
haemolysis reactions of different species in the genus Haemophilus are 
summarized in Table 3. H. influenzae and H. aegyptius can be differentiated 
using biochemical reactions, such as indole, urease and ornithine 
decarboxylase (Ledeboer and Doern, 2015; Munson et al., 2002). MALDI-
TOF mass spectrometry methods identify Haemophilus species with good 
accuracy regardless of the platform used (Couturier et al., 2011; Powell et al., 
2013).  
 
Table 3. Principal differential characteristics of Haemophilus-species. Modified from 
Ledeboer and Doern (2015).  
 Growth factor dependency Haemolysis 
 X V  
H. influenzae + + - 
H. aegyptius + + - 
H. haemolyticus + + + 
H. ducreyi + - - 
H. parainfluenzae - + - 
H. parahaemolyticus - + + 
H. pittmaniae - + + 
H. paraphrohaemolyticus - + + 
 
 
H. influenzae frequently colonizes the upper airway, the lower respiratory 
tract and, rarely, the genital area of humans.  30 to 80% of humans carry 
noncapsulated H. influenzae in the nasopharynx. The carriage rate of type b-
strains in vaccinated populations is less than 1%. The virulence and spectrum 
of diseases caused by H. influenzae is greatly dependent on the existence of 
capsular polysaccharide and its serotype in individual isolates. Non-typeable 
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(NT, which is equivalent to noncapsulated) strains are associated with RTI 
and invasive infections are mainly caused by encapsulated type b-strains. 
Other capsular types (a, c, d, e and f) and also certain NT isolates may 
occasionally be involved in invasive infections (Ledeboer and Doern, 2015; 
Murphy 2009 a). NT H. influenzae has been and continues to be a major 
pathogen along with S. pneumoniae and Moraxella catarrhalis in acute otitis 
media among children throughout the world (Sierra et al., 2011; Ngo et al., 
2016; Sillanpää et al., 2016). There is some evidence, that H. influenzae is 
associated more frequently than other pathogens with recurrent and chronic 
otitis media (Casey et al., 2004; Hall-Stoodley et al., 2006). H. influenzae is 
also a common cause of other non-invasive infections such as sinusitis, 
exacerbation of chronic obstructive pulmonary disease (COPD), 
conjunctivitis and community acquired pneumonia. Invasive infections 
caused by H. influenzae type-b include purulent meningitis, epiglottitis, 
pneumonia, cellulitis, bacteremia and septic arthritis. These type-b diseases 
can be rapidly fatal without proper and prompt treatment, particularly in the 
cases of meningitis and epiglottitis. The conjugate-vaccines against type-b H. 
influenzae have decreased the numbers of invasive diseases among children 
in countries with wide-spread vaccination (Peltola, 2000). Among the low-
vaccination countries and among certain populations (native Americans and 
native Alaskan children), in spite of covering immunizations, type-b H. 
influenzae still circulates. All invasive infections can also be caused by 
nontypeable and other serotype strains, but only occasionally. Special types 
of infections caused by nontypeable strains are neonatal and maternal sepsis, 
endometritis and ovarian abscesses. Usually biotype IV strains (closely 
related to H. haemolyticus) are involved in these cases (Murphy, 2009 a.).  
2.1.1.3 Moraxella catarrhalis 
The genus Moraxella belongs to a diverse group of miscellaneous gram-
negative non-fermentative bacteria. The scientific classification is presented 
in Table 4.  
Table 4.Taxonomy of Moraxella catarrhalis (Brenner et al., 2005). 
Kingdom Bacteria 
Phylum Proteobacteria 
Class Gammaproteobacteria 
Kingdom Bacteria 
Phylum Proteobacteria 
Order Pseudomonadales 
Family Moraxellaceae 
Genus Moraxella 
Species Moraxella catarrhalis 
 27 
The morphology of this group varies widely as it includes species that exist as 
long rods and other species as small cocci.  The common features of these 
bacteria are the lack of a fermentative metabolism and significantly better 
growth in aerobic than in an anaerobic atmosphere. Most species are 
catalase-positive, the oxidase reaction varies and they are non-motile or 
motile (Vanechoutte et al., 2015). 
Since the first descriptions in 1882 by Seiffert and in 1896 by R. Pfeiffer 
Moraxella catarrhalis has undergone a number of nomenclatural and 
taxonomic changes. It was first named (in Germany) as Mikrokokkus 
catarrhalis, and later classified as belonging to the genus Neisseria. In 1970 
a new genus Branhamella was established for the species but in the 1980s it 
was transferred to the genus Moraxella. There is still some debate about the 
“correct” classification of the species, however (Berk, 1990, Catlin, 1990; 
Enright and McKenzie, 1997). 
The genus Moraxella includes ~20 species, of which M. catarrhalis, M. 
osloensis, M. nonliquefaciens and M. lincolnii are commensal in human 
upper respiratory airways. Occasionally all species of the genus are isolated 
from superficial and even invasive infections in humans, though M. 
catarrhalis is the most frequent. Colonies of M. catarrhalis grow well on 
blood agars and/or chocolate agars, they are small (1–3 mm), smooth and 
opaque. The characteristic pinkish colour develops after prolonged 
incubation (48 hours). The colonies are easily misidentified as Neisseria 
species by colony morphology after overnight incubation. However, the 
typical sliding of colonies across the agar surface, when pushed by a loop, is a 
specific feature for M. catarrhalis. In gram-staining, M. catarrhalis appears 
as a small gram-negative diplococcus. M. catarrhalis is strongly oxidase, 
catalase and DNase positive. The ability to hydrolyse ester-linked butyrate 
groups is an easy way to separate M. catarrhalis from members of the 
Neisseria group in clinical laboratories, and several commercial methods are 
available for this purpose (Vanechoutte et al., 2015; Murphy 2009 b; 
Speeleveld et al., 1994). MALDI-TOF mass spectrometry has shown good 
performance in identifying M. catarrhalis isolates (Matthew et al., 2015).  
M. catarrhalis colonizes upper respiratory tract of humans. The rate of 
colonization is affected by age. Between 1 and 5% of healthy adults carry M. 
catarrhalis in the upper airways. Among children the colonization rate may 
be up to 100% among certain populations. Other factors may also be 
involved: regional factors, season, environmental conditions, hygiene, living 
conditions, genetic characteristics of the population and host factors. 
Pneumococcal vaccines have also changed the patterns of nasopharyngeal 
flora: non-vaccine S. pneumoniae strains, NT H. influenzae and M. 
catarrhalis have replaced the vaccine-type S. pneumoniae (Murphy 2009 b).  
The clinical manifestations of M. catarrhalis infections are: otitis media 
in children, the exacerbation of COPD in adults, sinusitis, pneumonia in 
older adults and, occasionally, bacteremia. M. catarrhalis is one of the 
predominant causes of otitis media and bacterial sinusitis along with S. 
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pneumoniae and H. influenzae. It is detected in 15–20% of middle ear fluid 
(MEF) and sinus aspirate samples by culture an even more often (47%) with 
polymerase chain reaction (PCR) methods (Wald, 2011; Ngo et al. 2016; 
Sillanpää et al., 2016). M. catarrhalis is involved in mixed infections more 
often than other bacterial species and it is also found in children with a 
previous history of acute otitis media (Sillanpää et al., 2016). It also appears 
more often in young children (<12 months), and causes less spontaneous 
perforation of the tympanic membrane than other bacterial species (Kilpi et 
al., 2001; Broides et al., 2009). Immunodeficiency and other underlying 
diseases such as diabetes, malignancy and cardiopulmonary diseases are 
associated with M. catarrhalis bacteremia and pneumonia in adults (Murphy 
2009 b).   
2.1.2 Other respiratory pathogens 
Other bacterial pathogens reported in MEF samples of children include: 
Streptococcus pyogenes, Staphylococcus aureus, Chlamydia trachomatis, 
Pseudomonas aeruginosa and members of the Enterobacteriaceae family. 
Additionally, bacteria with unclear significance in otitis media pathogenesis 
have been detected, such as Alloiococcus otitidis and Turicella otitidis among 
others (Ngo et al., 2016; Sillanpää et al., 2016). Viruses also play a significant 
role in children’s otitis media, either alone or in combination with bacterial 
pathogens (Ruohola et al., 2006).   
Several other bacterial species including anaerobic bacteria, 
staphylococci, Enterobacteriaceae, Pseudomonas aeruginosa, β-haemolytic 
streptococci, Mycoplasma pneumoniae, and Chlamydia pneumoniae are 
involved in other upper and lower respiratory tract infections such as 
bronchitis, pharyngitis, chronic sinusitis and pneumonia (Ruuskanen and 
Heikkinen, 2011; Korppi and Järvinen, 2011).  
 
2.2 Antimicrobial resistance among respiratory 
pathogens 
Penicillin/ampicillin with and without ß-lactamase-inhibitor, macrolides, 
sulfamethoxazole-trimethoprim and tetracyclines antimicrobial agents have 
been most commonly used for RTI in Finland (Rautakorpi et al., 2001). The 
resistance rates of S. pneumoniae, H. influenzae and M. catarrhalis for these 
are shown in figures 1, 2 and 3. The figures are modified from the database of 
the national FINRES-surveillance (FINRES, 2015), where susceptibility 
results from Finnish clinical microbiology laboratories are combined. Over 
90% of M. catarrhalis produce β-lactamase and are therefore resistant to 
ampicillin (not shown in Fig. 3).  
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Fig.1. Antimicrobial resistance (%, y-axis) among S. pneumoniae in 2008?2015. R = 
resistant, I = intermediate; Pen = penicillin, Ery = erythromycin, SxT = sulfamethoxazole-
trimethoprim, Tcy = tetracycline. Modified from FINRES (2015). 
 
 
Fig. 2.  Antimicrobial resistance (%, y-axis) among H. influenzae in Finland 2008–2015. R 
= resistant; Amp = ampicillin, Amc = amoxicillin-clavulanic acid, Azm = azithromycin, SxT 
= sulfamethoxazole-trimethoprim, Tcy = tetracycline. Modified from FINRES (2015).  
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Fig. 3. Antimicrobial resistance (%, y-axis) among M. catarrhalis in Finland 2008–2015. R 
= resistant; Amc = amoxicillin-clavulanic acid, Ery = erythromycin, SxT = 
sulfamethoxazole-trimethoprim, Tcy = tetracycline. Modified from FINRES (2015). 
2.2.1 ß –lactams 
The ß–lactam ring is the common structure among all ß-lactam antibiotics. 
The first and best characterized compound in this group is classical G-
penicillin (Fig.  4), a natural ß-lactam.  
 
 
 
 
Fig. 4. The chemical structure of penicillin showing the four-membered β-lactam ring in 
the middle of the molecule. Modified from Walsh and Wencewicz (2016).  
This group can be divided into two subgroups on the basis of chemical 
structures: penicillin-related and cephalosporin-related ß-lactams. 
Additionally, non-classical ß–lactams have been developed (monobactams 
and carbapenems). Benzylpenicillin and its derivative, ampicillin, are the 
primary ß-lactams used for RTI. Benzylpenicillin is effective against gram-
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positive bacteria; ampicillin is effective against gram-negative bacteria as 
well (Livermore and Williams, 1996).  
All ß-lactams are bactericidal antimicrobial agents and act by inhibiting 
the synthesis of peptidoglycan, which is the major component of the bacterial 
cell wall. Peptidoglycan is essential for bacteria, because it protects the cell 
contents from excessive osmotic pressure and also maintains the shape of the 
cell wall. The ß–lactams bind to the D-alanyl - D-alanine transpeptidases and 
carboxypeptidases that mediate the cross-linking of adjacent sugar chains to 
form the peptidoglycan net-like structure. This binding is covalent and 
thereby blocks the building of peptidoglycan. Hence, these enzymes are 
called penicillin binding proteins (PBPs). Bacteria have different patterns of 
PBPs, which vary by molecular weight, function and affinity to different ß-
lactams. For instance, the PBP1a in gram-negative bacilli is a bifunctional 
transpeptidase/transglycocylase, whereas PBP4 is a carboxypeptidase. The 
affinity of different ß-lactams for different PBPs also depends on the bacterial 
species (Livermore and Williams, 1996).  
2.2.1.1 Streptococcus pneumoniae 
S. pneumoniae is susceptible to many antibiotics including the ß–lactams, 
macrolides, fluoroquinolones and vancomycin. However, acquired resistance 
has emerged in recent decades, especially against penicillin and macrolides. 
The resistance rates vary greatly in different parts of the world and the 
increase has been associated with an increased use of antibiotics in several 
studies (Musher, 2009; Riedel et al., 2007; Bergman et al., 2006; van de 
Sande-Bruinsma et al., 2008; Mera et al., 2006; Goossens et al., 2005). Dual- 
and multiresistance has also increased dramatically in some countries 
(Soares et al, 1993; Felmingham et al., 2005). Penicillin has traditionally 
been the drug of choice in both invasive and non-invasive pneumococcal 
infections. Since the 1970s, however, resistance to penicillin has increased in 
several countries and consequently penicillin is no longer the first line 
antibiotic used for invasive infections unless the susceptibility of the 
microorganism is known. The evaluation of changes in resistance is 
somewhat complicated, because the definitions of susceptibility and 
resistance have changed. Recently these definitions have been adjusted with 
respect to the site of infection (CLSI, 2015; EUCAST 2016). Penicillin non-
susceptibility doubled (from 8 to 16%) among Finnish invasive 
pneumococcal isolates between 2002 and 2006 (Siira et al., 2009). 
2.2.1.2 Haemophilus influenzae 
Ampicillin and its analog, amoxicillin, are the primary ß-lactams for 
superficial infections caused by NT H. influenzae. The drugs of choice for 
invasive infections that are usually caused by type b-strains are cefotaxime 
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and ceftriaxone (Murphy 2009 a). Ampicillin resistance has been moderate 
in the 2000s worldwide ranging from 1 to27% in the USA and Europe 
(Morrissey, 2005; Perez-Tallero et al., 2010; Critchley et al., 2007; FINRES 
2015).  However, Asian countries including South-Korea and Japan had 
much higher resistance rates (58.5% and >50%; Bae et al., 2010; Sanbongi et 
al., 2006).  
The outer membrane (OM) of gram negative bacteria typically 
complicates the penetration of ß-lactam antibiotics into the host cell. 
However, the OM of H. influenzae is quite permeable to ß-lactams, hence the 
MIC-values for ampicillin are lower than in other gram-negative bacteria 
such as Enterobacteriacae (Livermore and Williams, 1996). 
2.2.1.3 Moraxella catarrhalis 
Since the first ß-lactamase producing M. catarrhalis strains appeared in 
Finland at the end of the 1970s, their number increased very quickly to 95.9% 
in 1995 (Nissinen et al., 1995; Manninen et al., 1997). Ampicillin resistance 
has remained at a high level thereafter (FINRES, 2015). The proportion of ß-
lactamase-producers in other European countries has been in excess of 90%, 
in studies published in the 21st century, and virtually all isolates have been 
fully susceptible to amoxicillin-clavulanic acid, but resistance to cefaclor and 
cefuroxime was reported to be moderate to substantial in some countries 
(Schito et al., 2000; Morrissey et al., 2008; Gracia et al., 2008).  
2.2.2 Macrolides and ketolides 
Macrolides are a group of bacteriostatic antibiotics that share a common 
structure, which is formed by a 14 or 15 membered lactone ring (Leclerq and 
Courvalin, 2002). The chemical structure of erythromycin is shown in Fig. 5. 
 
 
 
Fig. 5.The structure of erythromycin showing the 14 –membered lactone-ring. Modified 
from Walsh and Wencewicz (2016). 
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Erythromycin, clarithromycin and roxithromycin are the commercially 
available macrolides in Finland. In addition, one azalide antibiotic, 
azithromycin, and one ketolide antibiotic, telithromycin, are also 
commercially available. The term macrolide hereafter refers to the whole 
group of antibiotics that possess the lactone ring.  
Macrolides act by blocking protein synthesis in the 23S rRNA subunit of 
the bacterial ribosomes. They bind near to the peptidyltranferase centre in 
domain V of the 23S rRNA subunit. The binding site is located in a tunnel, 
which is a channel for the growing peptide chain. Other major components in 
the tunnel are the ribosomal proteins L4 and L22. Erythromycin inhibits 
bacterial protein synthesis by blocking this tunnel (Leclerq and Courvalin, 
2002). 
2.2.2.1 Streptococcus pneumoniae 
Erythromycin resistance increased among pneumococci in all parts of 
Finland from 1997 to 2002 and a significant association was found between 
erythromycin resistance and the consumption of azithromycin (Bergman et 
al., 2006). The increase has been reported separately among invasive isolates 
between 2000–2006 and ranged from 7% to 28% (Pihlajamäki et al., 2003; 
Siira et al., 2009). Resistance in non-invasive S. pneumoniae isolates rose to 
a peak in 2011 among children, after that resistance has decreased (FINRES, 
2015). Erythromycin resistance has been especially high among penicillin-
non-susceptible pneumococci (up to 62%) (Pihlajamäki, 2000; Kaijalainen et 
al., 2002). The 10 year surveillance in USA, UK, France, Italy and Spain 
reveals a similar trend for erythromycin and azithromycin but in Germany 
the increase was slower (Felmingham et al., 2005). The same study also 
reported a dramatic increase in the prevalence of penicillin-erythromycin co-
resistance in France, Spain and USA. Two recent studies from Portugal and 
Spain show moderate increase in erythromycin resistance from 21.6% in 
1996 to 25.3% in 2007 among all pneumococcal isolates (Simoes et al., 2011) 
and from 6.3% in 1997 to 19.4% in 2009 among invasive serotype 6C-isolates 
(Rolo et al., 2011). In England and Wales, on the other hand a sharp fall from 
24% to 3% for erythromycin resistance among children’s invasive isolates has 
been documented after the introduction of the heptavalent conjugate 
pneumococcal vaccine (PVC7) in 2006 (Henderson et al., 2010). Earlier, 
erythromycin resistance in pneumococci from blood cultures has been 
strongly associated with serotype 14, covered by the PVC7–vaccine in the UK 
(Birtles et al., 2004). In Canada, on the other hand resistance has increased 
especially among non-PVC7–serotypes (Wierzbowski et al., 2014).  
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2.2.2.2 Haemophilus influenzae 
Numerous susceptibility surveillance studies including the macrolides have 
been conducted for H. influenzae. No indications of acquired resistance were 
detected for erythromycin in a Finnish study in 1995, though the authors 
stated the known fact that erythromycin has only a marginal effect on H. 
influenzae (Nissinen, et al., 1995). A point prevalence study from the USA, 
determined MIC-values for erythromycin, clarithromycin and azithromycin 
(Doern et al., 1997). In lack of breakpoints for erythromycin the results were 
compared in the light of MIC-values. The conclusion was that azithromycin 
was most active against H. influenzae (MIC50/ MIC90 –values 2/2 μg/ml). 
The corresponding values for erythromycin and clarithromycin were 
considerably higher (8/8 μg/ml and and 8/16 μg/ml, respectively; Doern et 
al., 1997). European H. influenzae isolates from two periods (1997–1998 and 
2002–2003) also showed higher MIC50/MIC90 values for clarithromycin (8/8 
μg/ml) than for azithromycin (1/2) and telithromycin (2/2) (Fluit et al., 
2005). The relatively low MIC values for, azithromycin especially, has 
allowed this antiobotic to be an option in the treatment of respiratory tract 
infections including those caused by H. influenzae. For example, in Finland 
97% of macrolides were used for upper respiratory tract infections (URTI) 
and they were the most frequently used antibiotics by this indication (28%), 
followed by amoxicillin (25%) and doxycycline (20%) (Rautakorpi et al., 
2001). Despite the good in vitro efficacy, the clinical efficacy of 
clarithromycin and azithromycin has been poor against H. influenzae (Dagan 
and Leibovitz, 2002).  
2.2.2.3 Moraxella catarrhalis 
Resistance to erythromycin among M. catarrhalis isolates has been 
moderate to low world-wide. The annual frequency of resistant isolates in 
Finland has varied between 1.9% and 5% (FINRES, 2015). In Estonia, 12% 
resistance to clarithromycin was reported in 2006 (Altraja et al., 2006). 
Another report of increased resistance comes from Italy, where between 5 to 
10% of isolates had MIC-values for azithromycin and clarithromycin in the 
intermediate range (Tempera et al., 2010). A study from Japan, reported that 
the macrolides: erythromycin, clarithromycin, azithromycin and 
telithromycin showed strong respective activities against M. catarrhalis 
(Niki et al., 2011). Telithromycin was more effective against ß-lactam-
resistant M. catarrhalis than azithromycin (MIC90 0.06 vs. 0.12 μg/ml) ( 
Leclerq, 2001). On the other hand, a global surveillance showed no 
substantial differences in the MIC-values of erythromycin and telithromycin 
for M. catarrhalis between the continents (Khan et al., 2010). 
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2.2.3 Sulfamethoxazole-trimethoprim 
Sulfamethoxazole-trimethoprim (co-trimoxazole) is a combination of 
trimethoprim and sulfamethoxazole (see chemical structures in Fig. 6), and 
are usually used in the ratio 5:1 for treatment of infections (Walsh and 
Wencewicz, 2016).  
 
 
 
 
 
Fig. 6. Chemical structures of sulfamethoxazole and trimethoprim, the componets of co-
trimoxaxzole. Modified from Walsh and Wencewicz (2016). 
 
The bactericidal effect is based on serial inhibition in the metabolic pathway 
of tetrahydrofolic acid (THFA) by the two components. THFA is essential for 
the synthesis of thymidine, methionine, glycine, adenine and guanine in both 
bacterial and mammalian cells. In contrast to human cells, bacteria are 
unable to absorb exogenous folates and are thus dependent of de novo 
synthesis of folates (except the genus Enterococci). The sulfonamide 
component inhibits the reduction of THFA in the presence of dihydrofolate-
reductase (DHFR). Trimethoprim inhibits the action of DHFR (Eliopoulos 
and Moellering, 1996). 
2.2.3.1 Streptococcus pneumoniae 
Resistance to sulfamethoxazole-trimethoprim shows high geographical 
variation, even within the same country. Variation in resistance also depends 
on specimen type and resistance to other antimicrobial agents. In general 
sulfamethoxazole-trimethoprim resistance in Finland has increased from 
4.5% in 1988?1990, among pneumococci (Nissinen et al., 1995) to nearly 
30% in 2009 (FINRES, 2015), and thereafter resistance decreased. 
Substantial differences in resistance were reported in different regions of 
Finland (5.1% to 72.7%) in 1997 (Pihlajamäki et al., 2001).  Total resistance in 
the USA was 23.5% in 2005?2006 (Chritchley et al., 2007). However, the 
resistance rate depended on penicillin susceptibility (5.1%) or non-
susceptibility (37.3–73.1%) (Chritchley et al., 2007). A remarkably high 
incidence of resistance (81%) was reported from Taiwan in isolates collected 
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in a tertiary care hospital for the 1984?1997 period. Resistance was more 
common in respiratory isolates (>90%) than in blood culture isolates (72%) 
and it was also more common in penicillin resistant isolates (100%) than in 
penicillin susceptible isolates (84.6%) (Hsueh et al., 1999).  
2.2.3.2 Haemohilus influenzae 
Sulfamethoxazole-trimethoprim resistance in H. influenzae was fairly low in 
Finland <5% at the end of the 1980s (Nissinen et al., 1995), but has since 
gradually increased to the range of 25–30% annually (FINRES, 2015). 
Globally the incidence was at the same level in 1999–2000 (Hoban and 
Felmingham, 2002), and was the same in the USA in 2005–2006 (Critchley 
et al., 2007). Substantially, higher resistance rates have been reported in 
selected populations: in the Arab Emirates (37.3%) of patients with 
community acquired respiratory tract infections, in Taiwan from pediatric 
rhinosinusitis isolates (40%), in Zambia in carriage isolates obtained from 
HIV-infected children (38– 56%) and in India carriage isolates from healthy 
schoolchildren (67.3%) (Senok et al., 2007; Hsin et al., 2010; Mwenya et al., 
2010; Jain et al., 2005).  
2.2.3.3 Moraxella catarrhalis 
Sulfamethoxazole-trimethoprim resistance among Finnish M. catarrhalis 
isolates has been low, only 2% in 2015 (FINRES, 2015). Earlier an increase 
from 0.5 to 14.5% over the 1995 to 1998 period in Finland has been reported 
(Manninen et al., 1997). Very low resistance rates have been reported in the 
2000s in other countries: 0% in Canada, 2.2% globally from the PROTEKT 
surveillance (Prospective Resistant Organism Tracking and Epidemiology for 
the Ketolide Telithromycin) study (Bandet et al., 2014; Hoban and 
Felmingham, 2002). Recently, in Taiwan 18.5% resistance for M. catarrhalis 
isolates against sulfamethoxazole-trimethoprim was reported (Hsu et al., 
2012). 
2.2.4 Tetracyclines 
The first tetracyclines were discovered in the 1940s and isolated from 
Streptococcus aureofaciens and Streptomyces rimosus. Tetracyclines are 
thus natural antimicrobial agents, although semisynthetic derivatives have 
been developed. The chemical structure of all tetracyclines and derivatives is 
based on a hydronaphtacene nucleus having four (the name “tetra” refers to 
four) fused rings (Fig. 7). Certain substitutions in this ring have resulted in 
semisynthetic compounds such as doxycycline and minocycline (Chopra and 
Roberts; 2001; Stratton 1996). 
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Fig.7. Structure of tetracycline molecule showing the four six-membered rings in the 
backbone of the molecule. Modified from Walsh Wencewicz (2016). 
 
Tetracyclines exist in lipophilic form that can pass through the cell 
membrane and can also exist in hydrophilic form that diffuses easily 
throughout the cytoplasm. They use OmpF-porins and OmpC-porins to 
permeate the bacterial cell wall in gram-negative bacteria. Tetracyclines form 
magnesium-chelates to pass through these cation-dependent channels. The 
lipophilic form is also understood to cross the cell wall and the cytoplasmic 
membrane of gram-positive bacteria. Tetracyclines inhibit protein synthesis 
at the ribosomal level by preventing the codon-anticodon interaction 
between tRNA and mRNA. Binding of tetracyclines to the 30S ribosomal unit 
is reversible (Chopra and Roberts, 2001; Roberts, 2003; Stratton, 1996). 
Tetracyclines are broad-spectrum bacteriostatic antibiotics that have 
activity against both gram-negative and gram-positive bacteria, intracellular 
organisms, such as chlamydiae, mycoplasmas and ricketsiae, and also certain 
eukaryotic organisms, such as Plasmodium falciparum and Entaoemba 
histolytica. RTI is, however, still the main indication for tetracyclines 
(Roberts 2003). 
2.2.4.1 Streptococcus pneumoniae 
 
Resistance to tetracycline has been moderate among S. pneumoniae in 
Finland. However, resistance has slightly increased: from 6.7% in 1995 to 9% 
in 2015 (Manninen et al., 1997; FINRES, 2015). Reports of resistance from 
other countries vary in the 2000s >90% in China (Hu et al., 2016), nearly 
60% in Pakistan (Zafar et al., 2016), 20% in Turkey (Torumkuney et al., 
2016) and 9% in the UK in (Blackburn et al., 2010). Dual-resistance and 
multiresistance has been reported in several studies, mostly with one or more 
of the following agents: penicillin, erythromycin and sulfamethoxazole-
trimethoprim (Maraki et al., 2010; Lee et al., 2010; Vanhoof et al., 2010; 
Calatayud et al., 2010; FINRES, 2015).  
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2.2.4.2 Haemophilus influenzae 
Tetracycline resistance in H. influenzae has been very low in Finland. 
Between 2008 and 2015 resistance has been <5% annually (FINRES, 2015). 
The PROTEKT-study reported 0.7% resistance for ß-lactamase-negative 
isolates and 16.6% for ß-lactamase-positive isolates globally in the 
1999?2000 period (Hoban and Felmingham, 2002). H. influenzae strains 
from sputum specimens in the UK were highly susceptible (99%) to 
tetracycline over the 2007–2010 period (Blackburn et al., 2011). Very recent 
surveillance studies report higher resistance levels in the Middle-East and 
Far-East countries (Zafar et al., 2016; Torumkuney et al., 2016; Hu et al., 
2016).  
2.2.4.3 Moraxella catarrhalis 
Very low prevalences (0–1.2%) of tetracycline resistance have been 
documented in Finland among M. catarrhalis-isolates over the 2008 to 2015 
period (FINRES, 2015).  Similarly, in the UK and Ireland 1999?2007 only 
0.2% resistance was reported for 1999?2007 (Morrissey et al., 2008), and 
1.1% resistance in Australia for the corresponding period (Pingault et al., 
2010).  
2.2.5 Resistance mechanisms 
Resistance mechanisms reported in pneumococci, H. influenzae and M. 
catarrhalis to the four antimicrobial groups are summarised in Table 5 and 
are described in detail under heading numbers from 2.2.5.1 to 2.2.5.4 
inclusive.  
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Table 5. Resistance mechanisms for β-lactams, macrolides, sulfamethoxazole-
trimethoprim (=SxT) and tetracyclines in S. pneumoniae, H. influenzae and M. 
catarrhalis.  
  Mechanism 
β -lactams β -lactamases 
H. influenzae TEM1,ROB1  
M. catarrhalis BRO1, BRO2 
Altered PBBs 
S. pneumoniae PBB1A, 2A, 2B, 2X 
H. influenzae PBB3A, 3B 
Macrolides Ribosomal methylation   
S. pneumoniae erm(A), erm (TR) 
H. influenzae erm(A), erm (B), erm(C), erm(F) 
Efflux pump 
S. pneumoniae mef(A), mef(E)  
H. influenzae mef(A) 
Modified target site 
S. pneumoniae Domain V of 23S rRNA (A2058G, A2059G) 
Ribosomal proteins (L4, L22) 
H. influenzae  Domain V of 23S rRNA (A2058G, A2059G) 
Ribosomal proteins (L4, L22) 
SxT Modified enzymes (trimethoprim, DHFR)   
S. pneumoniae Modified dhf 
Overproduction of enzyme (trimethoprim, DHFR) 
H. influenzae  ND 
Modified enzymes (sulfa, DHPS) 
S. pneumoniae sulA/folP 
H. influenzae  sul2, folP 
Tetracyclines Efflux   
H. influenzae  tet(B) 
M. catarrhalis tet(B) 
Ribosomal protection 
S. pneumoniae tet(M), tet(O) 
H. influenzae tet(M) 
 
 
2.2.5.1 ß–lactams 
Bacteria can become resistant to ß–lactams by several different mechanisms, 
namely: altered PBPs, impermeability, production of ß–lactamases and use 
of an alternative transpeptidase (Musher, 2009; Livermore and Williams, 
1996). 
In pneumococci, modifications in the PBPs 1A, 2A, 2B and 2X result in 
decreased affinity for the antibiotic and consequently decreased 
susceptibility (Linares et al., 2010). Low-level penicillin-resistance has been 
associated, especially with altered PBP2X, whereas PBP2B plays a vital role 
in clinically relevant resistance (Smith et al., 1993), although the final degree 
of resistance is presumably dependent on the collective action of multiple 
modified PBPs (Smith and Klugman, 1995).   
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Susceptibility to ß–lactams in H. influenzae can be predicted by 
susceptibility to ampicillin and two mechanisms have been confirmed to 
mediate resistance: production of ß–lactamase and/or altered PBPs 
(Tristram et al., 2007). The ß–lactamase-mediated resistance is more 
common in Europe (Fluit et al., 2005) and USA (Heilman et al., 2005) 
whereas altered PBPs with low affinity to ampicillin have become more 
prevalent in Japan (Hasegawa et al., 2006). ß–lactamase-mediated 
ampicillin resistance was first detected in H. influenzae in the 1970s; two 
types of ß–lactamases, TEM-1 and ROB-1 are found in clinical isolates. Both 
are active against ampicillin and amoxicillin and are easily inhibited by ß-
lactamase inhibitors, such as clavulanic acid (Tristram et al., 2007). The 
PROTEKT study (1999–2003) reported the global distribution of these 
enzymes, which showed the predominance of TEM-1 over ROB-1 (93.7% vs. 
4.6%); only in Mexico and USA did the proportion of ROB-1 exceeded 10%. 
In the same study a minor proportion (1.2%) of isolates were found to carry 
ß-lactamases, but was negative for TEM-1 and ROB-1-genes in PCR. The 
susceptibility pattern, however, was similar, which suggested a novel type of 
ß-lactamase or mutations in the previously described types (Farrell et al., 
2005). ESBL ß–lactamases have been transferred to H. influenzae by 
recombination techniques but this has not yet been detected in clinical 
isolates (Tristram et al., 2005). A recent study by Schaar et al. (2014) showed 
that ß–lactamases of nontypeable H. influenzae isolates are present in outer 
membrane vesicles.  
ß-lactamase-negative, ampicillin resistant isolates (BLNAR) carry altered 
PBPs and show reduced susceptibility to ampicillin and ampicillin–ß-
lactamase-inhibitor combinations and also other ß-lactams, particularly to 
cefaclor and cefuroxime. H. influenzae has eight PBPs (IA, IB, 2, 3A, 3B, 4, 5 
and 6). PBP3A and 3B are encoded by the fstI gene and modifications in 
these proteins have been confirmed to be responsible for the BLNAR-
resistance (Tristram et al., 2007). In most surveillance studies of BLNAR, 
MIC values ≥2 μg/ml for ampicillin has been applied for categorization  
(Doern et al., 1997; Fluit et al., 2005; Skaare et al., 2010). The study by 
Ubukata and colleagues (2001), however, showed that even isolates with 
ampicillin MIC values of 1 and 2 μg/ml, had mutations in ftsI genes, which 
resulted in decreased affinity of PBP3. There is also evidence, that BLNAR 
strains with high ampicillin MIC values (range 8-16 μg/ml) possess an 
additional resistance mechanism, AcrAR efflux pump (Kaczmarek et al., 
2004). Yet, another mechanism behind high MIC values is ß-lactamase 
enhanced BLNAR –resistance, that is an isolate carrying both ß-lactamase 
and altered PBPs (named as BLPACR for ß-lactamase positive amoxicillin-
clavulanate resistant, Doern et al., 1997). The cloning of TEM-3, 4 and 5–
type ß-lactamase genes into H. influenzae showed that they alone did not 
elevate MIC values against 3rd generation cephalosporins. However, together 
with altered PBP3, isolates containing these ß-lactamase genes became 
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resistant against cefotaxime. BLPACR-strains with TEM-1 type ß-lactamases 
remained susceptible for cefotaxime (Bozdogan et al., 2006).  
Two types of ß-lactamases have been found in M. catarrhalis: BRO-1 and 
BRO-2 of which BRO-1 is the more common. Globally the BRO-1/BRO-2 
ratio is 95%/5%, although adults are more likely to be colonized by the BRO-
2 type strains (Khan et al., 2010). Both enzymes are encoded by 
chromosomal genes, are phenotypically similar, they differ from each other 
only by one amino acid, they are easily transformed from cell to cell and are 
inactivated by ß-lactamase inhibitors. BRO-1 strains have higher MIC values 
for ampicillin, which is probably a matter of quantitative difference (Verduin 
et al., 2002.) A variant, named BRO-3 has also been reported. The substrate 
profile was identical with BRO-1 and BRO-2, but in isoelectric focusing the 
banding patterns were different (Christensen et al, 1991). This finding has 
not been confirmed in other studies. Recently, it was shown that outer 
membrane vesicles produced by M. catarrhalis also carry ß-lactamases 
among other compounds such as virulence factors.  This feature also protects 
other upper respiratory tract pathogens from amoxicillin-induced killing, 
although these pathogens may otherwise be susceptible (Schaar et al., 2011). 
A single report has been published of TEM-ß-lactamase in M. catarrhalis 
(Robledano et al., 1987). There are also data from Europe about ß-lactamase 
negative strains showing penicillin resistance (Berk et al., 1996). These 
isolates have not been studied further and the penicillin resistance 
mechanism is unknown.  
 
2.2.5.2 Macrolides 
Ribosomal modification by methylation was the first identified mechanism of 
erythromycin resistance. The erm gene codes the production of methylases, 
which add one or two methyl groups to the binding site of erythromycin at 
nucleotide A2058 (E. coli numbering) of 23S rRNA. This is a key binding site 
for the antibiotic (Walsh and Wencewicz, 2016). In pneumococci the erm 
gene is usually carried in transposons, which are easily exchanged even 
between different bacterial species. Today, several erm genes have been 
identified; and of these erm(B) is predominant in S. pneumoniae isolates in 
Finland (Rantala et al., 2005). The erm(A) subclass erm(TR) genes have also 
been detected in pneumococci, but to a lesser degree (Farrell et al., 2002; 
Syrogiannapoulos et al., 2001). Active efflux is another major erythromycin 
resistance mechanism in pneumococci. The genes responsible for this efflux 
are mef(A) and mef(E), which are transferred in transposons. These genes 
have 90% similarity in the nucleotide sequences and are considered variants 
of the same gene (Roberts, 2008; Leclerq and Courvalin, 2002). The 
resistance genes that confer macrolide resistance differ geographically: the 
efflux-genes have predominated, in Finland, Scotland, the USA and Germany 
(Rantala et al., 2005; Amegaza et al., 2002; Farrell et al., 2002; Bley et al., 
 42 
2011). The prevalences for mef and erm(B) in Canada are almost equal 
(Wierzbowski et al., 2007), whereas, in Russia, Korea and Spain erm(B) is 
more prevalent (Reinert et al., 2008; Bae and Lee, 2009; Calatayud et al., 
2010). Individual isolates may have both mef and erm-genes (Farrell et al., 
2002).  
The first reports of macrolide-resistant pneumococci with no known 
mobile resistance genes were published in 2000, first after selection in vitro 
by macrolide passage (Tait-Kamradt et al., 2000 a) and later also in clinical 
isolates (Tait-Kamradt et al., 2000 b). Those studies reported mutations in 
domain V of the 23S rRNA (C2611A, C2611G, A2058G and A2059G, E. coli 
numbering) and the ribosomal protein L4. Later, several mutations in the 
23S rRNA, L4 and also in ribosomal protein L22 have been reported which 
conferred macrolide resistance in pneumococci (Pihlajamäki et al., 2002; 
Farrell et al., 2003; Davies et al., 2005; Leclerq and Courvalin, 2002).  
A study of clinical H. influenzae-isolates compiled in the Alexander-
project (an international, multicentre, longitudinal surveillance study of 
antimicrobial susceptibility among common respiratory pathogens), revealed 
that almost all strains had an efflux-mechanism, which pumps 
clarithromycin and azithromycin out of the bacterial cells. This was shown 
even in isolates, which were classified as being susceptible on the basis of 
CLSI-breakpoints. Only in a minority of isolates with MIC values <0.25 
μg/ml for azithromycin and <2 μg/ml for clarithromycin, well below the 
breakpoint values at that time (≤4 and ≤8, respectively), no indications of 
macrolide efflux was noted (Peric et al., 2003). The efflux was later shown to 
inhibit accumulation of telithromycin as well in H. influenzae –cells 
(Bogdanovich et al., 2006).  
When 18 H. influenzae isolates were exposed to clarithromycin and 
azithromycin in a multistep resistance selection study (max. 50 days), >4-
fold increases were measured in MIC values. None of these resistant strains 
had acquired the resistance genes erm(A), erm(B), mef(A/E) or ere(A) (an 
esterase conferring resistance to erythromycin), but 10/18 isolates had 
mutations in the respective macrolide binding site of the 23S rRNA or 
ribosomal proteins L4 and L22 (Clark et al., 2002). These findings were later 
confirmed in clinical isolates (Peric et al., 2003, Bogdanovich et al., 2006). A 
single mutation in the L22-ribosomal protein of a resistant mutant 
(substitution of arginine by proline at position 88, R88P) was not, however, 
able to confer high-level macrolide resistance, if the efflux was not present 
(Peric et al., 2004). Although the mobile macrolide resistance genes erm(A), 
erm(B), mef(A/E) or ere(A) were not detected in these studies, the mef-gene 
has been experimentally transferred to H. influenzae from a S. pneumoniae 
donor (Luna et al., 2000). The first proof of these mobile genes in clinical H. 
influenzae isolates were reported among cystic fibrosis (CF) patients. The 
first report included four isolates from a single patient with CF. The strains 
were isolated over a nine month period and showed increasing macrolide 
resistance. The 3rd and 4th isolates had high MIC values (>256 μg/ml) to 
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azithromycin and erythromycin and carried 2?4 copies of erm(B) and mef(A) 
genes (Ojo et al., 2006). Another study collected 106 azithromycin and/or 
erythromycin resistant or intermediately resistant strains in a placebo-
controlled treatment study of children with CF. Half of all patients received 
long-term azithromycin therapy and the other half received placebo. All 
isolates carried one or more of the following macrolide resistance genes: 
erm(A), erm(B), erm(C), erm(F) and mef(A). Selected isolates were screened 
for L4 and L22-mutations, but these results were negative (Roberts et al., 
2011).  
The low prevalence of macrolide resistance among M. catarrhalis may be 
the reason why resistance mechanisms have not been studied in this 
microorganism. Mef genes have been found in other gram-negative clinical 
isolates, such as Acinetobacter junii and Neisseria gonorrhoeae and have 
been transferred by conjugation to M. catarrhalis (Luna et al., 2000). The 
conjugation was successful even, when the gram-positive species, S. 
pneumoniae, was used as a donor. That study, however, did not state the 
level of resistance in the recipient-isolates after conjugation. In the 
taxonomically closely related species N. gonorrhoeae, methylase genes and 
mutation in the 23S rRNA have also been reported (Roberts et al., 1999; 
Roberts, 2004; Ng et al., 2002).  
2.2.5.3 Sulfamethoxazole-trimethoprim 
Intrinsic resistance to sulfamethoxazole-trimethoprim appears mainly in 
enterococci, because those bacteria can incorporate folates into their cells. 
Several other bacterial species can absorb thymidine, but this does not 
contribute to resistance (Tegmark-Wisell et al., 2008). Modified DHFR is the 
most important mechanism to confer resistance to trimethoprim, and 
nowadays several different types of resistant DHFRs have been recognized in 
gram-negative bacteria (Kehrenberg and Schwarz, 2005; Grape et al., 2007; 
Roberts, 2002). Most of the DHFRs are spread in transposons or transferable 
gene cassettes (Huovinen et al., 1995). Gram-positive bacteria may also carry 
altered DHFRs, but hitherto only three resistant genes have been described. 
Resistance to sulfonamides is mediated by altered dihydropteroate synthases 
(DHPS). Several DHPS genes have been identified: sulI and sulII in gram-
negative bacteria, sulIII in mycobacteria, sulA in pneumococci, and folP in 
several bacterial species (Huovinen et al., 1995; Fermer et al., 1997; 
Swedberg et al., 1998; Padaychee and Klugman, 1999; Roberts, 2002).  
Sulfamethoxazole-trimethoprim resistance in S. pneumoniae was first 
reported in 1972 (Howe and Wilson, 1972). The individual MIC values of 
either component of the binary antimicrobial correlated with the MIC values 
of both combined in that study. However, in another study the MICs for the 
trimethoprim component correlated more strongly than the 
sulfamethoxazole component (Adrian and Klugman, 1997). Those authors 
also found more isolates that were resistant to the sulfamethoxazole but were 
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susceptible to the combination, than resistant to trimethoprim but 
susceptible to sulfamethoxazole-trimethoprim combination. This led to the 
conclusion that trimethoprim resistance is the essential factor in 
sulfamethoxazole-trimethoprim resistance. A single change in the DHFR 
(replacement of isoleucine-100 by leucine) due to mutation in the 
chromosomal dhf gene confers resistance to trimethoprim in pneumococci by 
inhibiting the binding site (Adrian and Klugman, 1997; Pikis et al., 1998; 
Marimon et al., 2006). Some additional mutations have been described, 
which may further decrease the susceptibility (Maskell et al., 2001).  
The chromosomal sulA-gene, or folP as suggested by Haasum et al. (2001) 
encodes DHPS in S. pneumoniae. Several base insertions that lead to 
repetitions in the amino acid sequence of the DHPSenzyme have been 
detected in sulfonamide resistant isolates (Maskell et al., 1997; Schmitz et al., 
2001). Apparently the insertions lead to an expansion and conformational 
changes in the region of the sulfonamide binding site, thus preventing its 
enzymatic effect (Padayachee and Klugman, 1999).  
Only few published studies can be found about trimethoprim resistance 
mechanisms in H. influenzae and the data so far are somewhat speculative. 
de Groot and co-workers (1988) concluded first that trimethoprim resistance 
is due to overproduction of chromosomally located DHFR. In a further study 
(de Groot et al., 1991) they found structurally altered DHFRs with reduced 
affinity to trimethoprim in the resistant isolates. No plasmid-mediated 
resistance mechanisms were found in the study conducted by Powell (1991), 
who concluded that transposon encoded DHFRs, common in 
Enterobacteriacae, had not spread to H. influenzae at that time (Powell, 
1991).  Sulfonamide resistance was investigated in clinical H. influenzae 
isolates of 24 higly resistant strains obtained from the UK and Kenya (Enne 
et al., 2002). The sul1 was not detected, whereas sul2 was present in 8/24 
isolates and the remainder (16/24) had a 15 bp insertion in the chrosomal 
folP gene. This altered folP was transformed H. influenzae isolates into a 
susceptible recipient and the folP gene alone was able to increase the MIC 
value to sulfamethoxazole.  
Currently, no studies have been published that demonstrate the 
mechanisms of resistance to sulfonamides or trimethoprim in M. 
catarrhalis. One study exists (Rådström et al., 1992), in which a sulfonamide 
susceptible Neisseria meningitidis isolate acquired resistance. It was 
suggested that the increase in resistance was acquired by the uptake of DNA 
from a sulfonamide resistant strain. The origin of the resistance mediating 
gene, however, remained unsolved in naturally resistant isolates. In this 
context the authors mentioned, that in M. catarrhalis altered dphs-genes 
were not found. M. catarrhalis is naturally resistant to trimethoprim due to 
trimethoprim-insensitive DHFR (Huovinen 1987).  
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2.2.5.4 Tetracyclines 
Three mechanisms mediating tetracycline resistance in bacteria have been 
identified: efflux mediated resistance that exports tetracycline out of the cell, 
and ribosomal protection whereby binding of tetracycline molecule to the 
ribosome is prevented and enzymatic inactivation of tetracycline (found only 
in strict anaerobes). Today, 27 different genes that encode the efflux have 
been identified, a further 12 genes for the ribosomal protection mechanism 
and three genes for the enzymatic inactivation. In addition, one gene, with 
unknown mechanism is known, but does not seem to be related to either 
efflux or ribosomal protection (Roberts et al., 2012). The genes are named as 
tet (for tetracycline resistance) or otr (oxytetracycline resistance) (Roberts, 
2005 and Roberts 2002).  
Tetracycline resistance in pneumococci results from the acquisition of one 
of two resistance determinants, tet(M) or tet(O). Both genes encode 
ribosomal protection proteins, which are able to dissociate tetracycline from 
the ribosome (Connell et al., 2003.) In both cases the release of tetracycline 
is strictly dependent on GTP (Burdett 1996; Trieber et al., 1998). The tet(M) 
gene is carried in conjugative transposons of the Tn916-family, which 
transfer readily between several gram-negative and gram-positive bacterial 
species. The Tn-like elements also contribute to multi-drug resistance by 
integrating into larger mobile genetic elements, which encode other 
antimicrobial resistance determinants ( Rice, 1998). 
Until recently tetracycline resistance in H. influenzae was associated only 
to the tet(B) gene, which encodes an efflux-mechanism. tet(B) is located on 
conjugative plasmids. Two other tetracycline-resistance mediating genes 
have been found in other Haemophilus species: tet(M) and tet(K) in H. 
ducreyi and H. aprophilus. Both genes express ribosomal protection 
proteins, though only tet(M) does so in H. ducreyi. The tet(M) had been 
earlier transferred to H. influenzae in vitro by conjugation (Tristram et al., 
2007.) In a recent study, tet(M) was found in clinical H. influenzae isolates 
(Soge and Roberts, 2011) Three strains isolated from CF patients, were 
resistant to erythromycin and tetracycline. All isolates carried both tet(B) 
and tet(M) genes and two of these isolates were able to transfer tet(M) to an 
Enterococcus faecalis recipient.  
Four highly resistant M. catarrhalis strains have been characterized in the 
USA and in England in 1991 with respect to tetracycline resistance 
determinants. All carried tet(B) genes, which were non-transformable 
(Roberts et al., 1991).  
2.3 Susceptibility testing methods 
In vitro susceptibility testing in a clinical laboratory has two goals: to detect 
resistance in a particular isolate to antimicrobial agents, which are normally 
effective and to assure susceptibility to drugs of choice in the particular 
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infection (Jorgensen and Ferraro, 2009). Resistance and susceptibility may 
be confirmed by several methods. For the most part, laboratories use 
methods, which measure the ability of the antimicrobial agent to inhibit 
growth of the particular isolate, these include: the broth microdilution 
method (BD), the disk diffusion method (DD) and the gradient diffusion 
method. The result is reported, depending on the method, as quantitative 
(MIC) or qualitative (susceptible, S, intermediate, I or resistant, R). Another 
approach is to detect the actual mechanism behind the resistance (Jorgensen 
and Ferraro, 2009). For the first mentioned methodological approach there 
have been, historically, multiple guidelines with different breakpoints that 
divide bacteria into susceptible and resistant strains and attempts to 
harmonize this issue have been launched (Baquero, 1990, Kronvall et al., 
2011). Different guidelines (standards) also include some methodological 
differences. The results of testing may be very different depending on the 
applied method and standard used. The differences also vary according to the 
antimicrobial agent, bacterial species and the genetic mechanism behind the 
resistance. For these reasons, the comparison of resistance data from 
different sources is complex (Cotter and Adley; 2001 Jones et al., 2004; 
Rodriguez-Martinez et al., 2011).    
2.3.1 Guidelines for antimicrobial susceptibility testing 
 
In order to harmonize antimicrobial breakpoints in Europe, the European 
Society for Clinical Microbiology and Infectious Diseases (ESCMID) initiated 
the European Committee on Antimicrobial Susceptibility testing (EUCAST). 
Members of the EUCAST committees are chosen on the basis of their 
expertise in different areas of antimicrobial resistance and susceptibility 
testing. The work for setting breakpoints began in 2002 and the first 
breakpoints, quality control (qc) tables and the DD manual for susceptibility 
testing of bacteria were published in the end of 2009. All EUCAST 
information needed to perform and interpret antimicrobial susceptibility 
testing is freely available online (including the data behind the breakpoints, 
www.eucast.org; EUCAST, 2016). Finnish laboratories implemented the 
EUCAST method in 2011. The clinical MIC breakpoint is an MIC value that 
indicates probable therapeutic success. MIC breakpoints are defined on the 
basis of epidemiological cut-off values (ECOFFs, cut-off values), that 
distinguish wild-type strains from those carrying resistance mechanisms 
combined with pharmacodynamic and pharmacokinetic information. These 
breakpoints are calibrated in zone diameter values using an “MIC coloured 
histogram technique” (Fig. 8) (Kronvall et al., 2011; Wolfensberger et al., 
2013; EUCAST, 2016). 
The Clinical Laboratory Standards Institute (CLSI), previously The 
National Committee for Clinical Laboratory Standards, NCCLS) is a non-
profit organization in USA, which produces standards and guidelines for 
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healthcare. Contrary to the EUCAST documents, the CLSI guidelines are not 
freely available. The Subcommittee for Antimicrobial Testing within this 
organization is composed of representatives from different fields: 
professional and governmental experts and representatives from 
pharmaceutical and diagnostic industry. The breakpoint setting in CLSI is 
based on correlating zone diameters to the corresponding MIC values (Fig. 
9). It is assumed that the correlation between the inhibition zone size and 
MIC value is linear. MIC-values converted to logarithms are plotted against 
corresponding zone in millimeters (arithmetic scale). After regression 
analysis a straight regression line with best fit is drawn and from this line any 
break-points defined for MIC-values can be converted to analogous values on 
the mm-scale (Jorgensen and Turnidge, 2007).  
 
 
 
 
 
Fig. 8. An example of an MIC-coloured histogram used in the breakpoint setting by 
EUCAST (Kalhmeter, 2015). Reprinted with the kind permission of the copyright holder.  
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Fig.9. An example of the regression line –method for setting zone diameter breakpoints for 
tetracycline according to the CLSI –standard. MIC –breakpoints are marked with vertical 
arrows and corresponding zone diameters with horizontal arrows (Kronvall et al., 2011).  
Reprinted with the kind permission of the copyright holder.  
Eleven other susceptibility testing standards were  still being used in 
European clinical laboratories 2002: BSAC and Stokes in the United 
Kingdom, SFM in France, CRG in the Netherlands, DIN in Germany, Rosco 
in Belgium and Denmark, SRGA in Sweden, Czech in the Czech Republic, 
Mensura in Spain and a local guideline in Greece. Additionally national 
applications were used [e.g. FiRe (Finnish Study Group for Antimicrobial 
Resistance)–standard in Finland, which was adopted from the CLSI-
guidelines] (Bruinsma et al., 2002).  
2.3.2 Minimal inhibitory concentration 
 
Either an agar dilution or BD (macro- or microdilution) method can be used 
to determine the MIC –value of an antimicrobial agent. These methods 
involve preparing two-fold dilutions of the antimicrobial agent in a liquid 
medium or agar medium, which supports growth of the isolate. The 
antibiotic tubes or plates are inoculated with a standardized bacterial 
suspension (1-5 x 105 CFU/ml) and incubated overnight. The tubes or agar 
plates are examined with the naked eye or by automatic readers to define the 
lowest concentration of the agent e.g. 2 μg/ml, which prevents growth of the 
isolate (Fig. 10). This concentration represents the MIC value.  
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Fig.10. An example of determination of MIC values using BD - method on a 96–well 
microtiter platform (Sensititre®). The antimicrobial agents are in the wells in increasing 
concentrations. The spots indicate that the concentration is not able to inhibit the growth 
of the isolate. Photo is courtesy of Thermo Fisher Scientific. Copying is prohibited.  
If the MIC-value is lower than the tissue concentration of the antibiotic at the 
infection site, then the isolate is considered susceptible (S) to the 
antimicrobial agent and the infection can be treated with normal dosage of 
the antibiotic. If the MIC value is correspondingly higher than its tissue 
concentration at the site, then the isolate is resistant (R) and normal dosage 
is not sufficient to achieve inhibition of the pathogen. Most guidelines 
include an interpretation area intermediate (I), which indicates that the 
isolate tolerates higher concentrations than normal and the inhibitory 
concentration cannot be achieved unless the drug is concentrated at the site 
of infection. The intermediate-category acts as a buffer between susceptible 
and resistant categories and is also meant to prevent false results due to the 
inaccuracy of the method itself. The broth and agar-dilution methods are too 
laborious and too slow to be used in a clinical microbiology laboratory 
setting. They are, however, the recommended reference methods for 
antimicrobial susceptibility testing (Amsterdam 1996; Jorgensen and Ferraro 
2009; EUCAST 2016 and CLSI 2015).  
Gradient diffusion methods, e.g. the E-test® (Epsilometer Test, 
(bioMerieux, developed originally by Ab Biodisk), are widely used to define 
MIC values. The tests are based on agar diffusion. A plastic strip with a 
predefined, continuous gradient of the antimicrobial agent on one side and 
concentration scale on the other is placed with its antimicrobial 
impregnated-side face down onto an inoculated agar plate. The antimicrobial 
agent is rapidly released generating a stable gradient. After incubation an 
elliptical clear zone is formed and the intersection point, where the ellipse 
meets the strip indicates the MIC-value as read from the concentration scale 
(Fig. 11). The method has been evaluated for many pathogenic microbes, 
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including fastidious and anaerobic bacteria and yeasts, and it is considered a 
suitable alternative to the BD and agar dilution methods (Jorgensen et al., 
1991). Other commercial applications similar to the E-test have been 
introduced recently are: M.I.C Evaluator™ by ThermoFisher Scientific and 
MIC Test Strip™ by Liofilchem.  
 
 
 
 
Fig. 11. Gradient diffusion test for E. coli to define MIC values (E-test®). TZ = ceftazidime 
(MIC 2 μg/ml), TZL = ceftazidime-clavulanic acid (MIC > 4 μg/ml). Photo Pauliina 
Kärpänoja.  
2.3.3 The disk diffusion method 
Being flexible and simple, the DD method (Fig. 12) is most widely used for 
susceptibility testing in clinical laboratories. The agar diffusion method was 
first used for measuring penicillin concentrations in plasma and in the 1940s 
it was adopted for susceptibility testing. For this purpose, filter paper disks 
impregnated with fixed antibiotic concentrations were developed. The first 
standard for disk diffusion susceptibility testing was published in 1966 and 
was named the Kirby-Bauer method after the authors (Bauer et al., 1966).  
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Fig.12. The disk diffusion (DD) test for Klebsiella pneumoniae. The isolate is resistant to 
ampicillin (AMP) and ceftazidime (CAZ), susceptible to cefotaxime (CTX) and amikacin 
(AK). Photo: Pauliina Kärpänoja.  
Five years later, the World Health Organization (WHO) started a multicenter 
project to study the essential factors that influence the DD susceptibility 
testing. The report “International Collaborative Study” was published in 1971 
(Ericsson et al., 1971). This method is different from the Kirby-Bauer method 
in inoculum density and was named according to the report of the study 
group as ICS method (Acar and Goldstein, 1996). 
Several guidelines have been published since 1996. The common feature 
for all these is that the susceptibility result (S, I or R) is measured after 
incubation from the width of the inhibition zone that forms around the disk 
that was placed on an inoculated agar plate. The numerical value in 
millimeters is converted to the S/I/R scale using pre-set cut-off values.  
The outcome of the DD method is affected by several factors. The 
composition of the agar medium is a crucial matter; Muller-Hinton (MH) 
agar is the most widely used media. However, it does not support the growth 
of all clinically relevant bacteria. The MH-medium can be enriched with 
blood to help the growth of fastidious bacteria. Other factors influencing the 
test results are: the inoculum density, timing of drug application, agar depth, 
incubation temperature, incubation time, growth characteristics of the test 
strain and the person to person variations in visual interpretation (Acar and 
Goldstein, 1996). The pre-set breakpoints, however, do not hold for all cases. 
Deviation occurs between different bacterial species and therefore most 
standards give breakpoints by species or species groups (Ericsson and 
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Sherris, 1971). Interlaboratory variation in determinations also occurs.  
However, careful standardization and quality assurance of the method can 
produce reliable and repeatable results (Nissinen et al., 1995; Manninen et 
al., 1995). 
2.3.4 Automated instrument systems 
Instrumentation of susceptibility testing may bring certain benefits: faster 
results, standardized techniques, the bias arising from visual reading can be 
avoided and the expert systems included in the software can help the 
interpretation of the results. There are a few studies about the effects of rapid 
susceptibility testing on different clinical and economical parameters. Two 
studies from USA, found significant benefits: the length of stay in hospital 
being shortened, the costs per patient were lower and the appropriate 
antibiotic therapy was initiated earlier (Doern et al., 1994; Barenfanger et al., 
1999). A Dutch study found that, pathogen-directed antibiotic treatment was 
initiated earlier and total antibiotic use was reduced, when the susceptibility 
result was made available to clinicians earlier (Kerremans et al., 2008). In 
contrast, another hospital in the Netherlands, reported no impact in the 
variables assessed (mortality, morbidity and costs), even though the 
susceptibility results were reported significantly earlier (Bruins et al., 2005).  
At least 12 automated instruments are available on the market for 
susceptibility testing, but three of them dominate: Phoenix® (Becton 
Dickinson), MicroScan® (Siemens) and Vitek2® (bioMerieux, Fig. 13). All 
three of these devices express susceptibility in MIC values and are supplied 
with software including an expert system. The MicroScan system is an 
incubator-reader system with manual inoculation, whereas the Phoenix and 
Vitek2-systems offer an additional automated inoculation (Winstanley and 
Courvalin, 2011; Jorgensen and Ferraro, 2009). 
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Fig.13. An example of automatic devices used for identification and susceptibility testing 
of bacteria (Vitek2®, bioMerieux). Photo Pauliina Kärpänoja.  
A cross-comparative study of the three methods for the susceptibility 
testing of S. pneumoniae, calculated the essential agreements (EA), which is 
the percentage of results within one dilution compared to the reference 
method and categorical agreements (CA), which is the interpretation within 
the same interpretation category as the reference method and compared 
them between all methods. The results were very similar for all instruments: 
Phoenix EA/CA 95.2%/99.3%, MicroScan 98.5%/99.5% and Vitek2 
95%/98.8% for all antimicrobials tested. The reference method was BD 
microdilution according to the CLSI guideline. Major errors (ME)  i.e. 
susceptible isolates reported as resistant were obtained most by the Vitek2 
system (9.6%, Phoenix 9.3% and MicroScan 6.2%). The number of very 
major errors (VME) i.e., resistant isolate reported as susceptible was also 
highest with the Vitek2 (2.4%, Phoenix 0.3%, MicroScan 0%) (Mittman et al., 
2009). 
In another comparative study 347 clinical isolates (enteric gram-negative 
bacilli, non-enteric gram-negative bacilli, staphylococci, streptococci, 
enterococci and other gram-positive cocci) were identified. Then 
susceptibility tests were performed with these three compared instruments. 
The findings reported as ME/VME were 4/2 (MicroScan), 3/0 (Phoenix) and 
1/3 (Vitek2). The total number of tests was 2723. The mean time taken to 
complete the antimicrobial susceptibility testing was shortest for the Vitek2-
instrument (9 h), followed by Phoenix (12 h) and MicroScan (20 h) 
(Sellenriek et al., 2005).  
Carbapenem resistance in Enterobacter-species was detected poorly by all 
three instruments. Sensitivity/specificity (%) readings were 100/0 for 
Phoenix, 82-85 /6-19 for MicroScan (two panels) and 74/38 for Vitek2. This 
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is partly explained by the fact that carbapenem resistance is often coupled 
with other resistance traits such as ESBL or AmpC combined with porin loss. 
There is considerable overlap in the MIC-values with these resistance 
mechanisms and consequently they poorly predict the carbapenemase 
resistance (Woodford et al., 2010).  
2.3.5 Direct detection of resistance mechanisms 
An old phenotypical method to detect resistance mechanism is the ß-
lactamase test. The most common procedures for the ß-lactamase test are 
chromogenic cephalosporin test, acidimetric test and iodometric method. All 
these are based on the same principle: the end product of ß-lactamase is 
visualized usually by colour change. For example, in the nitrocefin 
(chromogenic cephalosporin) test, the isolate studied is exposed to the 
nitrocefin disk. If ß-lactamase is produced, then the amide bond in the beta-
lactam ring will be hydrolyzed and a colour change occurs. This particular 
test detects most of the ß-lactamases (ESBLs and carbapenemases excluded) 
and it is therefore widely used. However, for instance staphylococci require 
induction to express the ß-lactamase production (Leitch and Boolayangor, 
1992). In this case the cloverleaf test (or Modified Hodge’s test, MHT) which 
requires an overnight incubation, can be used. The cloverleaf test detects the 
ability of the isolate studied to allow growth of a susceptible indicator-isolate 
in the presence of a ß-lactam-antibiotic in case ß-lactamase is produced 
(Kjällander and Myrbäck, 1964). Phenotypical tests are also used for 
detecting ESBLs, carbapenemases and AmpC-mediated resistance. The ESBL 
tests are based on the inhibitory effect of clavulanic acid and tatzobactam. 
The isolate is incubated with a cephalosporin and cephalosporin-clavulanate 
combination. The forms and different sizes of the inhibitory zones (disk test) 
or differences in MIC-values (E-test) indicate ESBL-production (Steward et 
al., 2001; Cormican et al., 1996). Carbapenemases are screened using MHT 
or by demonstrating the inhibitory effect of different compounds (clavulanic 
acid, boronic acid or chelating agents such as EDTA). These methods, 
however, always require genetic confirmation (Queenan and Bush, 2007; 
Seah et al., 2011; Pasteran et al., 2009). AmpC mediated resistance has been 
screened by using cefoxitin as an indicator. Resistant isolates were confirmed 
phenotypically using the double-disk synergy method i.e. cefoxitin+oxacillin 
(Polsfuss et al., 2011).  
2.3.6 Genetic and proteomic methods 
Instead of determining phenotypic susceptibility in an isolate, detecting the 
resistance gene(s), may offer some of the following advantages for the 
laboratory and clinician: 1. the test can be performed directly on the sample 
without culturing; 2. phenotypic susceptibility tests will not detect the 
resistance, if the resistance gene is not expressed; 3.  resistance may only be 
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manifested after prolonged incubation in slowly growing organisms, when 
phenotypic methods are used; 4.  resistance can be determined even for non-
cultivable bacteria and 5. culture of micro-organisms creates biohazard risks, 
which can be avoided by using direct genetic methods instead (Cockerill, 
1999). However, there are also many limitations of this approach. The major 
drawback is that resistance to one antimicrobial agent may be due to several 
different mechanisms. Furthermore, behind one mechanism tens or even 
hundreds of different genes may be involved and all of these must be sought. 
An example of this is cephalosporin resistance in Enterobacter species. 
Compared to adding new probes to a PCR test, adding one antibiotic disk 
onto an agar-plate is far more flexible.   
There are already a few commercial, molecular applications utilized in 
clinical microbiology. Methicillin resistant Staphylococcus aureus (MRSA) 
has been detected directly in different specimens (blood cultures, wounds, 
nasal swabs, and groin swabs) by several methods. For instance, the 
GenoQuick (HAIN Lifesciences), Xpert MRSA/SA (Cepheid), GenoType 
MRSA Direct (HAIN Lifesciences), Light Cycler (Roche) and GeneOhm Staph 
SR (Becton Dickinson) applications have been evaluated recently. The time 
required to get the result took 2–2.5 hours. Depending on the specimen type, 
sampling protocol and the test used, results have varied: sensitivity 57–98% 
and specificity 92.2–100% (Stamper et al., 2007; Scherlock et al., 2010; 
Bühlman et al., 2008; Wolk et al., 2009; Peterson et al., 2010). Other 
commercial applications include simultaneous identification and detection of 
rifampin resistance in Mycobacterium tuberculosis (Blakemore et al., 2010) 
and the probing of vanA/vanB  genes (conferring vancomycin resistance) in 
enterococci (Marner et al., 2011). Additionally, several in-house, multiplex 
PCR applications have been introduced (Fluit et al., 2001).  
Whole-genome sequencing (WGS) and next generation sequencing (NGS) 
techniques for the identification of antimicrobial resistance genes in bacterial 
whole genome data have been studied in recent years. High concordance 
99.74% (Zankari et al., 2013) with phenotypic susceptibility testing has been 
achieved with several bacterial species and antimicrobial agents. Although 
the costs and complexity of sequencing techniques have recently declined, 
there is no consensus yet of the optimal bioinformatics method (Clausen et 
al., 2016). However, WGS and NGS are likely to become common in 
diagnostic microbiology in near future. Phenotypic susceptibility testing is 
still needed as a complementary method e.g. to identify novel resistance 
mechanisms (Dunne et al., 2012). 
The MALDI-TOF MS method is based on protein analysis and is currently 
used in clinical laboratories for identifying bacteria and fungi. Recently other 
applications have been described, including the identification of 
antimicrobial resistance mechanisms. Carbapenemases in Enterobacteriacae 
species have been detected by analyzing the degradation products of 
carbapenem using MALDI-TOF MS after incubating these beta-lactamases 
with the the bacterial strain (Lasserre et al., 2015; Oviano et al., 2016). 
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Mather and colleagues (2016) differentiated accurately 98% of vancomycin 
intermediate (VISA) and vancomycin susceptible (VSSA) Staphylococcus 
aureus isolates by analyzing the presence or absence of any peak and the 
peak height of the MALDI-TOF spectra. Like the WGS approach, the MALDI-
TOF MS cannot probably entirely replace phenotypic susceptibility tests, but 
has its place as an additional tool for selected purposes to detect resistance 
mechanisms (Hrabak et al., 2013).   
2.4 Antimicrobial resistance and antimicrobial 
consumption 
Penicillin was introduced into clinical medicine in 1944. In the period from 
1946 to 1950 over 50% of originally susceptible S. aureus isolates worldwide 
had become resistant to penicillin. Plasmid mediated ß-lactamases were the 
cause of this resistance. This is considered the first indication of antibiotic 
use being associated with antimicrobial resistance (Livermore and Williams, 
1996). Since then, a number of studies have demonstrated the link between 
increased consumption and increased resistance at all ecological levels: in 
individual patients, hospital-settings, small communities, different 
geographical areas within one country, nationally and internationally. These 
studies cover different bacteria and antibiotic combinations. A positive 
association has been shown between consumption and resistance in carriers 
and also in clinical isolates (Arason et al., 1996; Bronzwater et al., 2002; 
Zervos et al., 2003; Bergman et al., 2004; McDougall et al., 2005; Malhotra-
Kumar et al., 2007). Studies that found the opposite association i.e. a 
reduction in the use of antimicrobial agents was followed by a decrease in 
resistance also exist (Seppälä et al., 1997; Hsueh et al., 2006; Gottesman et 
al., 2009; Lee et al., 2010). Evidence has also accumulated of persistent 
resistance in the absence of a selective pressure; this has been shown with 
Enterobacteriaceae and streptomycin, with E. coli and sulfonamide and with 
E. coli and trimethoprim. It seems that genetic linkage of the index resistance 
to other genetic resistance elements (mobile transposons, gene cassettes) 
might partly explain this phenomenon (Chiew et al., 1998; Enne et al., 2001; 
Sundqvist et al., 2010). Bacteria have been traditionally assumed to become 
less fit, when they acquire resistance genes. If that is the case, then one might 
expect susceptible strains to predominate over time, once the use of the 
specific antimicrobial is reduced. However, there are studies showing that in 
some cases resistance populations remain in the population despite 
removing the selective pressure indicating that resistance does not 
necessarily reduce fitness of the bacteria (Melnyk et al., 2014; Holmes et al., 
2016.)  
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2.4.1 The association between antimicrobial resistance and 
antimicrobial consumption with special reference to 
Streptococcus pneumoniae, Haemophilus influenzae and 
Moraxella catarrhalis 
The association between antimicrobial resistance and consumption has been 
reported in numerous studies. Many of these studies used S. pneumoniae 
(Table 6) and show a positive association between one antimicrobial use and 
its resistance in the streptococcus. Resistance may also persist despite a 
decrease in antimicrobial use. Many studies also indicate, that consumption 
of one antimicrobial agent may also be associated to resistance to another 
antimicrobial class.  
Similar studies on H. influenzae are less frequent (Table 7) but these still 
show a positive association between consumption and resistance.  
Only a few studies deal with the development of resistance in M. 
catarrhalis with respect to antimicrobial consumption. Between 1978 and 
1993 the number of ß-lactamase positive M. catarrhalis obtained from 
middle-ear-samples of children showed a bimodal increase in Finland: from 
0% in 1978 to 60% in 1983 and from 60% in 1988 to 80% in 1990. A 35-fold 
increase in the use of first and second-generation cephalosporins occurred at 
the same time with the second peak, and it had started a few years earlier 
(Nissinen et al., 1995). Macrolide consumption did not associate with the 
development of resistance in the study conducted by Cizman and colleagues 
(2001). In that study resistance rates were calculated from six years (1994-
1999) and it was not until 1999 that the first macrolide resistant M. 
catarrhalis was observed.  
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Table 6.  Association between antimicrobial use and resistance in S. pneumoniae.  
↑indicates increased, ↓decreased and ↔ unchanged use or resistance.  
Antimicrobial agent / 
consumption 
Antimicrobial agent / resistance Country / population / 
source of isolates 
Ref. 
    
Penicillin, low dose, 
long treatment 
Risk factor for carriage of 
penicillin resistant isolates 
France, children 3 - 6 
years 
Guillemot et al., 1998 
Macrolides ↑ Erythromycin resistance ↑ Spain Grazino et al., 2000 
 High-level penicillin resistance ↑   
Oral cephalosporins ↑ High-level penicillin resistance ↑   
Total β-lactams ↑ Erythromycin resistance ↑     
Macrolides ↑ Macrolide resistance ↑ Finland Pihlajamäki et al., 
2001 
Cephalosporins ↑ Macrolide resistance ↑   
Penicillins ↑ Macrolide resistance ↑   
Sulfamethoxazole-
trimethoprim ↑ 
Sulfamethoxazole-trimethoprim 
resistance↑ 
  
Cephalosporins ↑ Sulfamethoxazole-trimethoprim 
resistance↑ 
    
Macrolides ↑ Macrolide resistance ↑ Slovenia, RTI1) Cizman et al., 2001 
Macrolides ↑ Macrolide resistance ↔ Slovenia, invasive 
isolates 
  
Azithromycin ↑ Macrolide resistance ↑ Finland Bergman et al., 2006 
Macrolides ↑ Macrolide resistance ↑     
Total β-lactams ↑ Penicillin non-susceptibility ↑ USA, blood culture 
isolates 
Ruhe and Hasbun, 
2003 
Sulfonamides ↑ Penicillin non-susceptibility ↑   
Macrolides ↑ Penicillin non-susceptibility ↑     
Azithromycin ↑ Macrolide resistance ↑ Canada, national level Karlowsky et al., 2009 
Clarithromycin ↑ Macrolide resistance ↑   
Azithromycin ↑ Macrolide resistance ↔ Canada, regional level  
Clarithromycin ↑ Macrolide resistance ↔     
Macrolides ↓ Macrolide resistance ↔ Taiwan Hsueh et al., 2006 
Macrolides ↓ Macrolide resistance ↑ China Chen et al., 2009 
Ciprofloxacin ↑ Fluoroquinolone resistance ↑ Canada Adam et al., 2009 
1) RTI = respiratory tract isolates 
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Table 7.  Association between antimicrobial use and resistance in H.  influenzae.  
↑indicates increased, ↓decreased and ↔ unchanged use or resistance.  
 
Antimicrobial agent / 
consumption 
Antimicrobial agent / 
resistance Country / population Ref. 
Erythromycin ↑ Erythromycin resistance ↑ Sweden, children 
Ringertz and Kronvall, 
1987 
Total β-lactams ↑ Amoxicillin resistance ↑ Scotland  Seaton et al., 2000 
Macrolides ↑ Azithromycin resistance ↑ Slovenia Citzman et al., 2001 
Azithromycin, long-term 
treatment Clarithromycin resistance ↑ 
Holland, CF1) -
patients Phaff et al., 2006 
Amoxicillin ↓ Amoxicillin resistance ↓ Spain Garcia-Cobos et al., 2008 
Sulfamethoxazole-
trimethoprim ↓ 
Sulfamethoxazole-
trimethoprim resistance ↓     
 
1) CF = cystic fibrosis 
 
2.4.2 Resistance data in surveillance studies  
A common view today is, that surveillance of antimicrobial resistance is 
needed at many different levels: locally, nationally and internationally.  
Longitudinal investigations, which enable monitoring trends over time, 
provide the most valuable data (Williams and Ryan, 1998; Morris and 
Masterton 2002; Halstead et al., 2004). Several national, continental and 
international surveillance programmes and networks are underway. 
However, as Neu and colleagues (1992) pointed out, there is a lack of 
standardization of the reported data and some data are fragmented and 
anecdotal.  
Some specific projects/ of the surveillance programmes (e.g. the global 
Alexander-project, which focus on respiratory pathogens) rely on centralized 
susceptibility testing. The susceptibility results are considered reliable and 
comparable with this protocol (Felmingham et al., 2005). The global 
Antimicrobial Surveillance Program (SENTRY) and the Meropenem Yearly 
Susceptibility Test Information Collection (MYSTIC) utilize susceptibility 
testing results performed in several laboratories with common, well 
controlled methods (Rhomberg and Jones, 2009; Gales et al., 2011). The 
European Antimicrobial Resistance Surveillance Network, formerly the 
EARSS (EARSNet) by 2014 had collected resistance data from 29 EU/EEA 
countries starting from 2001. These data comprise routine susceptibility 
results provided by participating laboratories; the data are collected and 
compiled at the national level: such as the FiRe network (Finnish Study 
Group for Antimicrobial Resistance) in Finland (ECDC, 2015 a; Nissinen and 
Huovinen, 2000). Any variation in test methods between laboratories may 
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create a bias in such multilaboratory databases. The EUCAST organization 
aims, among other goals, at harmonizing break-points and standardizing 
methods to minimize this bias and to produce really comparable results 
between laboratories and countries (Kronvall et al., 2011).  
A major defect in a surveillance report may be the inclusion of duplicate 
data (two or more identical isolates from one patient included). It was shown 
in the early 1980s that trimethoprim resistance rate of urinary tract isolates 
obtained from hospital patients decreased from 49.1% to 39.4% in the 
dataset after excluding duplicates. The decrease was smaller among 
outpatients (from 17.5 to 15.7 %; Huovinen, 1985). Horvat and colleagues 
(2003) showed that the rate of methicillin resistant Staphylococcus aureus 
(MRSA) was lower, when duplicate isolates were removed from the database. 
The difference was significant, when calculated for all hospital units and 
separately for non-intensive care units, but not significant in the intensive 
care unit (ICU). A Swedish study excluded duplicate isolates of E. coli and S. 
aureus from a 14-year consecutive database using different time cut-off 
times. When the cut-off was 90–365 days, resistance decreased, but when a 
7–10 days cut-off was used, the effect was smaller among E. coli. Among S. 
aureus exclusion of duplicates resulted in small but systematic decrease in 
resistance. The authors, however, point out that one should not assume 
removing duplicate isolates always results in lower resistance rates 
(Sundqvist and Kahlmeter, 2007). There is no general agreement about what 
basis should be used to exclude duplicate isolates. For example, the 
WHONETsoftware (http://www.who) has different criteria that can be 
applied (first isolate only, most resistant isolate etc.; Morris and Masterton, 
2002). The CLSI-guideline (M39-A3, 2009) stipulates that the first isolate of 
a given species per patient per analysis period, irrespective of body site, 
including its antimicrobial profile or other phenotypic characteristics must 
be used in the calculation of frequencies. This approach was supported by the 
study by Shannon and French (Shannon and French 2002 a). 
The inclusion of screening samples in the resistance data may influence 
the outcome of resistance surveillance. Another  study by Shannon and 
French (Shannon and French, 2002 b), showed that annual figures for 
methicillin resistance among S. aureus isolates differed 6-10% (with a limit 
of 365 days set for duplicate exclusion), depending on whether screening 
specimens were included or excluded. The authors also stated that inclusion 
of screening samples creates bias towards resistance mainly because patients 
are screened for colonization only with methicillin-resistant S. aureus, but 
not for methicillin-susceptible S. aureus.   
The patient’s age, sample type and patient type (hospitalized, outpatient) 
affect the resistance level. In France, the numbers of penicillin non-
susceptible pneumococci were different in children and adults: blood 
cultures 27.8 and 32.5%, MEF-samples 60.2 and 27.5%, for children and 
adults respectively. Moreover, the decrease of penicillin-resistance in 
invasive infections was different in children at 46.4 to 29% compared to 
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adults from 43.4 to 32.7% (Kempf et al., 2011). A Finnish study of the 
invasive pneumococci characteristics between 2002 and 2006 reported that 
non-susceptibility for penicillin and erythromycin were highest among the 
age group 0–15 years (Siira et al., 2009).   
Resistance data can be presented in several formats, the optimal format 
has not, however, been resolved among researchers. MIC-data are often 
summarized as MIC50/MIC90 i.e. the concentrations at which 50% and 90% 
of isolates are inhibited, and also as a range of MIC values (Duenas et al., 
2011). This presentation model fits well for point-prevalence studies (Morris 
and Masterton, 2002). For continuing surveillance studies, such as the 
MYSTIC project, another presentation model has been introduced. The MIC 
results are expressed as the percentage of isolates inhibited at each drug-
concentration. The MIC scale in this format should be large enough (≥12 log2 
dilutions) to allow for minor drifts to be detected. The EARSNet surveillance 
collects the data as S/I/R results. However, the problems arising from this 
approach manifest as a lack of conformity, and no quantitative results 
available, which are acknowledged in the ECDC report (2015 a) . Reporting of 
MIC values would be preferred. This is not a common practice in the 
participating laboratories (ECDC, 2015 a).  
2.4.3 Consumption data 
Studies on the association between antimicrobial use and resistance present 
antimicrobial consumption data mainly in two ways: defined daily doses 
(DDD), or prescription rates (Monnet et al., 2004).  
The DDD is an internationally used unit for antimicrobial consumption, 
which was developed originally by the Nordic Council of Medicines in 
collaboration with WHO. The DDD is defined as the assumed average 
maintenance dose per day for a drug used for its main indication in adults. 
This value does not give exact figures of actual use of drugs, but an estimate 
of the overall consumption. An advantage of DDD is that is independent of 
price, currencies, package size and drug strength and is therefore considered 
a good measure to compare consumption between different populations 
(WHO Collaboration Centre, 2016). Outpatient antimicrobial use is often 
described as DDD/1000 inhabitants/day and is abbreviated in some studies 
as DID (Goossens et al., 2005). The drawback with measuring of 
antimicrobial consumption by DDD is that it does not provide information of 
the user (age, sex), the infection, the used dosage and whether the drug has 
been actually used. 
The Drug Utilization Research Group (DURG) established by WHO in 
1969 has recommended that international drug utilization studies classify 
drugs according to the ATC (Anatomic Therapeutic Chemical) system. In this 
system of classification, all drugs are categorized into 14 main groups 
according to the organ or system on which they act, in addition to their 
therapeutic, pharmacological and chemical properties (WHO Collaborating 
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Centre, 2016). Antibacterial agents are in the main class J, subgroup J01, 
Antibacterials for systemic use (Table 8).  
 
Table 8.  Antimicrobial classes according to the ATC/DDD-classification (adopted from 
WHO Collaborating Centre, 2015).  
J           Anti-infectives for systemic use 
  
J01  
 
Antibacterials for systemic use 
  J01A Tetracyclines 
  J01B Amphenicols 
  J01C β-lactam antibacterials, penicillins 
  J01D Other β-lactam antibacterials 
  J01E Sulphonamides and trimethoprim 
  J01F Macrolides, lincosamides and streptogramins 
  J01G Aminoglycoside antibacterials 
  J01M Quinolone antibacterials 
  J01R Combinations of antibacterials 
  J01X Other antibacterials 
 
 
In hospital settings, the DDD/100 patient admissions or patient days is a 
common way to present antimicrobial consumption instead of DDD/1000 
inhabitants per day (Schön et al., 2011). The Slovenian Consumption Study 
Group compared hospital antibiotic use in five countries with three data 
presentation models. They noted that depending of the model used, the 
outcome was different. When consumption was expressed as DDD/100 bed-
days, it was highest in Danish hospitals. If the model was DDD/100 
admissions, hospitals in Holland used the most antibiotics.  Finally, if the 
consumption was measured as DDDs/1000 inhabitants/day, it was highest in 
France (Cizman et al., 2011).  
Several, mainly point-prevalence studies present antimicrobial use based 
on the number of prescriptions rather than DDD (or DID) figures (Steinman 
et al., 2009; Amadeo et al., 2010; McClean et al., 2011). The result may be 
different from the DDD data. Mölstad and colleagues (2002) compared 
antibiotic prescription rates between 13 European countries from 1994 to 
1997. They found that the highest use of antibiotics occurred in Greece, 
followed by Spain and Belgium. Another study that covered almost the same 
period (from 1993 to 1997), reported sales of antibiotics in 15 European 
Union countries, showed that the consumption was highest in France, 
followed by Spain and Portugal (Cars et al., 2001). Their study used data 
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calculated as DDD/1000 inhabitants/day instead of the number of 
prescriptions. Moreover, a study by deWith and colleagues (deWith et al., 
2006) revealed remarkable differences in the relative increase of antibiotic 
use in one hospital in Germany, depending on the data format. The relative 
increase of total antibiotic use was 81% as measured by DDD/100 patient 
days in medical wards, but only 48% when the PDD (prescribed daily 
doses)/100 patient days was used. One reason for this was the use of 
amoxicillin-clavulanic acid with different dosage from the DDD by the WHO 
index. One problem with consumption figures independent of the data 
format is undoubtedly the unknown share of antimicrobial agents used as 
self-medication. In some countries (even in Europe), antibiotics may be 
purchased legally without prescription from pharmacies (Grigoryan et al., 
2006). For example, in Greece, 69-86% of pharmacists offered antibiotics 
without prescription for patients with high or low fever, and most of them 
offered even broad-spectrum agents (Contopoulos-Ionnadis et al., 2001).  
2.4.4 Antimicrobial use in Europe and Finland 
In Europe, total use of antimicrobial agents in 2014 was highest in Greece 
(34.0 DDD/1000 inhabitants/day) and lowest in the Netherlands (10.6 
DDD/1000 inhabitants/day) (ECDC, 2015 b). The consumption figures from 
30 European countries are shown in Figure 14.  
 
 
 
Fig.14. Total outpatient antibiotic use in 2014 in 30 European countries. Printed according to 
the ECDC Copyright and Limited Reproduction Notices (ECDC, 2015 b).  
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The use of antibiotics in Finland has slightly declined from 1990 to 2014 
from 17.9 to 16.33 DDD/inhabitants/day, Fig. 15, Fimea 2016).  
 
 
 
 
Fig. 15. Total use of the most popular antimicrobial agents in Finland 1990-2014 The 
consumption is expressed as DDD/1000 inhabitants/day (y-axis), modified from Fimea 
(www.fimea.fi, 2016).  
Tetracyclines were the most commonly prescribed antibiotics in Finland 
in the 1990 to 2014 period, whereas the consumption of penicillin 
(phenoxymethylpenicillin) and sulfamethoxazole-trimethoprim declined. In 
contrast, the consumption of amoxicillin, amoxicillin-clavulanic acid and 
fluoroquinolone consumptions increased over the same period (Fig. 16, 
Fimea, 2016).  
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Fig.16.   Consumption figures of the most used antimicrobial agents in Finland 1990-
2014. The consumption is expressed as DDD/1000 inhabitants/day (y-axis). Modified 
from Fimea (www.fimea.fi, 2016).  
Most (87.2%) of all the antimicrobial agents prescribed in Finland were 
used in the primary health care sector (ECDC, 2015, b).  
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3 AIMS OF THE STUDY 
The Finnish susceptibility testing standard (FiRe-standard) was developed 
during the 1990s in order to standardize the methods for determining 
antimicrobial resistance in clinically important bacteria. The standardization 
project had two main goals: to produce reliable susceptibility results for 
clinicians and to achieve comparable resistance data between clinical 
microbiology laboratories in Finland. The general aim of the present study 
was to complete the standardization in Finland and to evaluate the results 
achieved by the standardization project. Prior studies have shown 
considerable variations in the methods used in Finnish laboratories for 
susceptibility testing and thus there has been a lack of uniformity in the 
resistance data collected nationally. Moreover, severe problems have been 
found in detecting unusual resistance, especially among the main respiratory 
pathogens: Streptococcus pneumoniae and Haemophilus influenzae.  I have 
aimed in this thesis to evaluate how reliable the susceptibility results for 
these bacteria are in Finnish clinical microbiology laboratories and how 
resistance is affected by antimicrobial use.  
 
 
The specific aims of this study were: 
 
 
1. To validate the susceptibility testing method of Haemophilus 
influenzae for the national FiRe-standard with special reference to 
non-β-lactamase mediated ampicillin resistance (I) 
 
2. To study the association between sulfamethoxazole-trimethoprim 
resistance and consumption in three common bacterial respiratory 
pathogens (II) 
 
3. To assess the quality of Finnish resistance data of Streptococcus 
pneumoniae and Haemophilus influenzae by means of quality 
control results (III) 
 
4. To evaluate an automated susceptibility testing method for 
Streptococcus pneumoniae (IV) 
 
5. To identify the molecular mechanisms among macrolide resistant 
Haemophilus influenzae in Finland (unpublished). 
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4 MATERIALS AND METHODS 
4.1 Bacterial strains (I, III, IV, unpublished) 
Bacterial isolates used in study I, are summarized in Table 9. The isolates 
were used to validate the DD method for the susceptibility testing of H. 
influenzae for the national FiRe-standard.  
Table 9.  H. influenzae–isolates used in study I. UK NEQAS= United Kingdom National 
External Quality Assessment Services, ATCC = American Type Culture Collection. 
BLNAS = β-lactamase-negative, ampicillin susceptible, BLNAR = β-lactamase-negative, 
ampicillin resistant, ND = not determined. 
 
 
Phenotypical susceptibilities of the three UKNEQAS–originated isolates 
are based on the information from the quality control scheme organizer. Two 
reference laboratories (the Public Health Laboratory, Cambridge, England 
and the Quality Assurance Laboratory, UKNEQAS, Health Protect Agency, 
United Kingdom) have performed MIC testing for the isolates and they were 
categorized according to the BSAC standard. Reference MIC values for the 
ATCC collection strains were obtained from the CLSI standard of that time. 
H. influenzae isolate, ATCC49247, has been shown to carry a mutation in the 
ftsI gene that leads to altered PBP3 (GenBank accession number 
FM163678.1), (Skaare et al., 2010). The strains were selected for this study 
primarily on the basis of their BLNAS or BLNAR phenotypes.  
Isolate/Source Reference MIC values (mg/L)  
      
 Ampicillin Amoxicillin-
clavulanic 
acid 
Cefaclor Cefuroxime ?-lactamase 
      
1 (BLNAS) 0.25 1 ND ND negative 
UK NEQAS 1141      
      
2 (BLNAR) 8 16 - 32 ND 64 negative 
UK NEQAS 2550      
      
3 (BLNAR) 2 - 4 2 - 4 ND >4 – 12 negative 
UK NEQAS 5270      
      
4 (BLNAS) ND ND 1 - 4 0.25 – 1 negative 
ATCC49766      
      
5 (BLNAR) 2 - 8 2/1 – 16/8 12 - 32 3 negative 
ATCC49247      
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Bacterial isolates used in study III are presented in Table 10. The isolates 
are the quality control isolates for susceptibility testing of H. influenzae and 
S. pneumoniae according to the FiRe standard. 
Table 10.  Bacterial strains used in study III and their reference susceptibilities. S = 
susceptible, R = resistant, I = intermediate, ATCC = American type culture collection. 
Isolate Antimicrobial agent 
Expected result 
(mm) 
Expected result 
(MIC, μg/ml) SI/I/R 
S. pneumoniae 
ATCC49619     
 ceftriaxone  0.03?0.12 S 
 cefuroxime  0.25?1 S 
 chloramphenicol 23-27 2?8 S 
 clindamycin 19-25 0.03?0.12 S 
 erythromycin 25-30 0.03?0.12 S 
 oxacillin 8-12  R 
 meropenem  0.06?0.25 S 
 moxifloxacin 25-31 0.06?0.25 S 
 penicillin  0.25?1 I 
 tetracycline 27-31 0.12?0.5 S 
 sulfamethoxazole-trimethoprim 20-28 0.12/2.4-1/19 S 
 vancomycin 20-27 0.12?0.5 S 
H. influenzae 
ATCC49247     
 ampicillin  2?8 R1) 
 amoxicillin-clavulanic acid   R
1) 
 azithromycin 13-21 1?4 S 
 tetracycline 27-31 0.12?0.5 I 
 sulfamethoxazole-trimethoprim 24-32 0.03/0.59?0.25/4.75 S 
 
The protocol for quality control (qc) followed that described in the FiRe-
standard: when a new method is introduced, the qc should be performed 
daily for 30 days; after that the qc should be continually performed weekly 
and always, when new batches of agar-plates or disks are taken into use. 
Thereby, the minimum frequency can be calculated to be 52 times per year. 
The qc-results for these challenge strains were collected from 25 laboratories 
as inhibition zone diameters (mm) (DD tests) or MIC values (μg/ml).  
S. pneumoniae isolates used in study IV are presented in Table 11 and 
their susceptibility rates are shown in Table 12. The isolates were identified 
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using the VITEK® MS MALDI-TOF method (bioMerieux S.A. 69280 Marcy 
l´Etoile, France).  
Table 11.  S. pneumoniae isolates used to evaluate susceptibility testing methods. 
PHSOTEY= Päijät-Häme Social and Health Care Group.  
Isolate Source1) n 
S. pneumoniae Consecutive blood culture 
isolates (PHSOTEY) 
183 
S. pneumoniae, penicillin non-
susceptible 
Miscellaneous non-invasive 
specimens (PHSOTEY) 
46 
 
 
Table 12. Susceptibility of 229 pneumococcal isolates used in study IV by the broth 
dilution method (Sensititre®). 
Antimicrobial agent 1) S 
 
I 
 
R 
 
  n % n % n % 
Penicillin 
 Non-meningitis breakpoints 153/229 66.8 69/229 30.1 7/229 3.1 
 Meningitis breakpoints 153/229 66.8 0/229 0.0 76/229 33.2 
Cefotaxime 198/229 86.5 29/229 12.7 2/229 0.9 
Ceftriaxone 195/229 85.1 32/229 14.0 2/229 0.9 
Meropenem 
 Non-meningitis breakpoints 229/229 100.0 0/229 0.0 0/229 0.0 
 Meningitis breakpoints 199/229 86.9 30/229 13.1 0/229 0.0 
Moxifloxacin 228/229 99.6 0/229 0.0 1/229 0.4 
Levofloxacin 229/229 100.0 0/229 0.0 0/229 0.0 
Erythromycin 153/229 66.8 0/229 0.0 76/229 33.2 
Tetracycline 192/229 83.8 1/229 0.4 36/229 15.7 
Sulfmethoxazole-trimethoprim 160/229 69.9 8/229 3.5 61/229 26.6 
Vancomycin 229/229 100.0 0/229 0.0 0/229 0.0 
Linezolid 229/229 100.0 0/229 0.0 0/229 0.0 
 
1) Breakpoints according to EUCAST 2016. The breakpoints for penicillin and meropenem are provided 
separately for non-meningitis and meningitis isolates. S = susceptible, I=Intermediate, R=resistant. 
 
 
Table 13 shows three subsets of the H. influenzae isolates that were used 
to investigate the molecular mechanisms that conferred macrolide resistance 
(unpublished). 
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Table 13. H. influenzae isolates used for tracing macrolide resistance mechanisms.  
Year n Source Reference 
    
1988 - 1991 204 MEF1), children < 6 years, six Finnish 
laboratories 
Nissinen et al., 1995 
1999 - 2000 379 Consecutive clinical samples, all age 
groups, seven Finnish laboratories 
Unpublished 
 
2006 - 2011 130 MEF1) and NPS2) -samples from 
children with suspected otitis, two 
Finnish laboratories 
Ruohola et al., 2013 
1) MEF = middle ear fluid 
2) NPS = nasopharyngeal secretion 
4.2 Specimen collection and handling (I, III, IV, 
unpublished) 
All isolates were subcultured once when necessary, frozen at -70°C in 20% 
skimmed milk as stock cultures and drawn onto TSAB (tryptone soya agar 
with sheep blood, S. pneumoniae) or chocolate agar (H. influenzae) plates 
before analysis.  
4.3 Susceptibility testing methods (I, IV, unpublished) 
The DD tests in study I were performed in 26 clinical microbiology 
laboratories in Finland (FiRe laboratories). The isolates (Table 6), HTM agar 
plates (Oxoid Basingstoke, Hampshire, UK) and 6 mm paper disks (Oxoid) 
were prepared and delivered to the laboratories centrally from the 
Antimicrobial Research Laboratory, National Public Health Institute, Turku, 
Finland (currently National Institute for Health and Welfare). The following 
antimicrobials and disk concentrations were tested: ampicillin 10 and 2 μg, 
amoxicillin-clavulanic acid 30 (20+10) and 3 (2+1) μg, tetracycline 30 μg and 
sulfamethoxazole-trimethoprim 25 (1:19) μg. The inoculum was adjusted to 
0.5 on the McFarland scale and the inoculated plates were incubated for 16-
18 hours at 35±2°C, 5% CO2. Disk diffusion testing in study IV was 
performed on Muller-Hinton for fastidious bacteria (MH-F) agar plates 
(www.eucast.org), otherwise the testing was as described above.  
The E-test® gradient strip (bioMerieux S.A. 69280 Marcy l´Etoile, 
France) was used in studies III and IV to define MIC-values. The inoculum 
was adjusted and plates were incubated as presented in the previous section.  
Vitek2® (bioMerieux S.A. 69280 Marcy l´Etoile, France), an automated 
susceptibility testing system with the novel AST-GP74 card was evaluated in 
susceptibility testing on pneumococci (IV). The testing was performed 
according to the manufacturer´s instructions. Briefly: the inoculum was 
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prepared from an overnight culture, adjusted to McFarland 0.5, and used to 
inoculate the susceptibility testing card. The cards were overlaid to the 
Vitek2 instrument for incubation and interpretation. Results of 
pneumococcal susceptibility tests were compared to the broth dilution 
method (BD, Sensititre®), performed in the EUCAST Development 
Laboratory (Växjö, Sweden). 
The MIC values for azithromycin, clarithromycin and telithromycin were 
determined by the E-test (see method on the previous sections) in order to 
trace the macrolide resistance among H. influenzae (unpublished). Only 
azithromycin and clarithromycin were tested in the 2006?2011 period 
because telithromycin strip was not available then. Isolates resistant to any 
antibiotic (n=6) were selected for further investigations (EUCAST-
breakpoints, www.eucast.org).  
All methods were controlled by using S. pneumoniae ATCC49619 and H. 
influenzae ATCC49247 as the appropriate reference.  
4.4 Resistance data (II) 
The annual resistance data for sulfamethoxazole-trimethoprim among S. 
pneumoniae, H. influenzae and M. catarrhalis were obtained from FINRES 
reports between 1998 and 2004. FINRES reports (in 1998 FINMAP report) 
have been compiled from the routine susceptibility testing results from 21 to 
27 (annual variation) Finnish laboratories. These laboratories are members 
of the FiRe network (www.finres.fi/) and they represent laboratories of the 
the public healthcare service and laboratories serving the private healthcare 
sector. These laboratories are estimated to cover over 95% of all resistance 
data produced in Finland. The data are reported as numbers and percentages 
of resistant isolates of all isolates studied in the laboratory. If the number of 
tested isolates fell below 30/laboratory/year, the data were excluded. 
Regional (by central hospital districts, n=21) results were combined for the 
study (i.e. when several laboratories reported results for one central hospital 
district). These surveillance data are based on results of the DD method and 
in a few laboratories of the E-test® method. The DD tests were performed 
and interpreted according to the national FiRe-standard (paralleling the 
CLSI-guideline). The quality control programme included susceptibility 
testing of S.pneumoniae ATCC49619 and H. influenzae ATCC49247 as 
internal quality controls and proficiency testing programmes by Labquality 
(www.labquality.fi) and UKNEQAS (www.ukneqasmicro.org). 
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4.5 Antimicrobial consumption data (II) 
The antimicrobial consumption data of sulfamethoxazole-trimethoprim (II) 
were obtained from Fimea (Finnish Medicins Agency, formerly Finnish 
National Agency of Medicines, www.fimea.fi/). These data are expressed as 
DDD per 1000 inhabitants per day. The consumption figures used in study II 
for comparing regional use to regional resistance are based on the sales from 
wholesalers to pharmacies (the use in hospitals is not included) on the 
assumption that this portion represents the use of these antibiotics in 
community health care. These regional consumption data were collected over 
a seven-year period (1997 to 2003 inclusive) from 21 central hospital 
districts.  
4.6 Detection of macrolide resistance genes and 
mutations in Haemophilus influenzae  (unpublished) 
Six isolates showing decreased susceptibility to at least one of the following 
agents: clarithromycin, azithromycin and/or telithromycin, were tested for 
macrolide resistance genes and mutations known to confer macrolide 
resistance. H. influenzae colonies from solid media were suspended in water. 
The suspension was heated in a heating block at 95 to 100 ° C for 10 minutes. 
This crude extract of total DNA was used for PCR reactions. The presence of 
following genes was studied: erm(A), erm(TR), erm(B), erm(C), erm(F) and 
mef(A). The primers that were used for PCR and PCR conditions are listed in 
Table 11.  Positive controls for the erm and mef genes as described previously 
(Pihlajamäki et al., 2002) and chromosomal DNA from a Bacteroides fragilis 
strain including erm(F) gene (kindly provided by Prof. Charlotta Enlund, 
Karolinska Institutet, Stockholm, Sweden) were included in the PCR 
reactions. 
Mutations at positions 2058 and 2059 (E. coli numbering) of the genes 
coding for domain V of 23S rRNA were analysed using the pyrosequencing 
method after PCR. Haanperä and co-workers (2005) have previously 
described the procedure in detail (see Table 14 for primers and details of the 
PCR reactions).  
Sequencing of the genes encoding for the ribosomal proteins L4 and L22 
was performed using an ABI PRISM Big Dye Terminator Kit (Applied 
Biosystems, Foster City, California). Primers used for PCR and subsequent 
sequencing, as well as the PCR conditions, are also presented in Table 14.  
The sequences were compared to H. influenzae Rd KW20 strain (NC 
00907, Genome Sequence Data Base accession number L42023). 
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Table 14.  Primers used for PCR and sequencing reactions and PCR conditions  
Gene Use Direction Primer sequence (5´?3´) 
 
PCR conditions 
     
erm(A)1) PCR Forward 
Reverse 
TCTAAAAAGCATGTAAAAGAA 
CTTCGATAGTTTATTAATATTAGT 
10 min. at 95oC (one cycle), 
1 min. at 94oC, 1 min. at 
48oC, 1 min. at 72oC (30 
cycles), 5min at 72?C 
erm(TR)2) PCR Forward 
Reverse 
CTTGTGGAAATGAGTCAACGG 
TTGTTCATTGGATAATTTATC 
10min. at 94?C (one 
cycle),30 s at 94oC, 30 s at 
51oC, 1 min. at 72oC (38 
cycles) 
erm(B)2) PCR Forward 
Reverse 
GAAAAGGTACTCAACCAAATA 
AGTAACGGTACTTAAATTGTTTAC 
10min. at 94?C (one cycle), 
30 s at 94oC, 30 s at 51oC, 1 
min. at 72oC (38 cycles)) 
erm(C)1) PCR Forward 
Reverse 
TCAAAACATAATATAGATAAA 
GCTAATATTGTTTAAATCGTCAAT 
10 min. at 95oC (one cycle), 
1 min. at 94oC, 1 min. at 
40oC, 1 min. at 72oC (40 
cycles), 5 min at 72?C 
erm(F)3) PCR Forward 
Reverse 
CGGGTCAGCACTTTACTATTG 
GGACCTACCTCATAGACAAG 
10 min. at 94oC (one cycle), 
30 s min. at 94oC, 30 s at 
50oC, 2 min. at 72oC (35 
cycles) 
mef(A)2) PCR Forward 
Reverse 
CTATGACAGCCTCAATGCG 
ACCGATTCTATCAGCAAAG 
10min. at 94?C (one cycle), 
30 s at 94oC, 30 s at 51oC, 1 
min. at 72oC (38 cycles) 
23S 
rRNA4) 
PCR Forward 
Reverse 
TAAGGTAGCGAAATTCCTTGTCG 
(23SV_univF-1926) 
Bio-CGACCGCCCCAGTAAACT 
(Bio_23SV_univR_2259) 
10 min. at 95oC (one cycle), 
15 s at 95oC, 15 s at 61 oC, 
30 s at 72 oC (35 cycles)  
Domain V 
of 
23SrRNA 
Pyrosequencing  CCGCGGCTAGACGG 
(23SV_Hinf_seq) 
 
L45) PCR  Forward 
Reverse 
TTAAGCCGGCAGTTAAAGC 
CACTTAGCAAACGTTCTTG 
10 min. at 95 oC (one 
cycle), 30 s at 94 oC, 30 s at 
53 oC, 45 s at 72 oC (35 
cycles) 7 min at 72?C 
L225) PCR  Forward 
Reverse 
CGGCAGATAAGAAAGCTAAG 
TGGATGTACTTTTTGACCC 
10 min. at 95 oC (one 
cycle), 30 s at 94 oC, 30 s at 
53 oC, 45 s at 72 oC (35 
cycles) 7 min at 72?C 
 
1) Sutcliffe et al., 1996 
2) Figueira et al., 2004 
3) Roberts et al., 1999 
4) Haanperä et al., 2005 
5) Peric et al., 2005 
 
4.7 Statistical methods (I, II, III, IV) 
Whonet 5.3 software (http://www.who.int/drugresistance/whonetsoftware/) 
was used to store the results (I, III), for calculating the susceptibilities (I, III) 
and for drawing the histograms (I). SPSS for Windows statistical software 
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was used to calculate the means and standard deviations (SD) sensitivities, 
specificities and ranges (I).  
In study II, a linear mixed model for repeated measures was used to 
model the association between regional resistance and regional antimicrobial 
consumption of the previous year. The resistance rates of S. pneumoniae, H. 
influenzae and M. catarrhalis in the 21 central hospital districts were 
compared separately to local consumption figures of sulfamethoxazole-
trimethoprim. The percentage of resistant strains was taken as the dependent 
variable whereas the antimicrobial consumption and time were the 
explanatory variables. A random effects model with time and consumption as 
a fixed effect and the intercept representing the random effect was fitted. 
Mixed models were fitted using the Proc Mixed in the SAS System for 
Windows version 8.02. The level of statistical significance was set at p-values 
below 0.05. 
The CA,  EA, false susceptible rate (FSR), numbers of minor errors (mE), 
ME and VME were calculated according to the Food and Drug 
Administration  (FDA) guidelines (2009) and previous reports (Skaare et al., 
2015).  
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5 RESULTS  
5.1 Susceptibility of Haemophilus influenzae (I, 
unpublished) 
5.1.1 Validation of the disk diffusion method 
Study I was undertaken to validate the disk diffusion susceptibility testing 
method of H. influenzae for the FiRe standard. The 26 laboratories 
participating in this study produced a total of 128 results (mm) for ampicillin 
10 μg (Amp 10) disks and 129 results for ampicillin 2 μg (Amc 2), amoxicillin-
clavulanic acid 30 μg (Amc 30) and amoxicillin-clavulanic acid 3 μg (Amc 3) 
disks. Interpretation of the results was based on the NCCLS breakpoints 
(currently the CLSI) breakpoints applied in 2004 and on the suggested 
breakpoints to lower concentration ampicillin according to Zerva (1996). 
These same breakpoints were used to lower concentration amoxicillin-
clavulanic acid, as well. The results of each isolate for these two antimicrobial 
agents are presented in Table 15. Resistant and intermediate categories were 
combined for the analysis. Isolates 3 and 5, which were defined as BLNAR 
strains, were categorized more accurately with the low concentration disks. 
The result was not as evident for isolate 2 (BLNAR). False resistant results 
were provided equally for isolates 1 and 4, which were defined as BLNAS 
strains. 
The calculated sensitivities and specificities for each test (disk) are 
summarized in Table 16.  The sensitivity to detect the BLNAR resistance for 
both antibiotics was better when low concentration disks were used. 
Specificities were as good (ampicillin) or slightly better with the high 
concentration disks (amoxicillin-clavulanic acid). 
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Table 15.  Results of ampicillin and amoxicillin-clavulanic acid disk diffusion susceptibility 
tests obtained from 26 laboratories. BLNAS = β-lactamasenegative, ampicillin 
susceptible, BLNAR = β-lactamasenegative ampicillin resistant. UKNEQAS = United 
Kingdom National External Quality Assurance Services. ATCC = American type culture 
collection.  
Isolate Interpretations Inhibition zone diameters 
 Disk S % R+I % Mean (SD) Range 
1 (BLNAS), UKNEQAS 1141 Amp 10 81 19 25 (±5) 16?38 
 Amp 2 88 12 21 (±5) 06?30 
 Amc 30 96 4 25 (±5) 16?36 
 Amc 3 80 20 19 (±4) 09?26 
2 (BLNAR), UKNEQAS 2550 Amp 10 28 72 19 (±6) 06?28 
 Amp 2 24 76 13 (±5) 06?23 
 Amc 30 36 64 17 (±6) 06?28 
 Amc 3 24 76 10 (±6) 06?24 
3 (BLNAR), UKNEQAS 5270 Amp 10 38 62 20 (±4) 13?30 
 Amp 2 0 100 10 (±2) 06?14 
 Amc 30 65 35 29 (±4) 15?31 
 Amc 3 4 96 12 (±2) 06?17 
4 (BLNAS), ATCC49766 Amp 10 96 4 29 (±4) 21?36 
 Amp 2 92 8 23 (±4) 14?30 
 Amc 30 96 4 28 (±5) 18?36 
 Amc 3 92 8 22 (±3) 14?28 
5 (BLNAR), ATCC49247 Amp 10 20 80 20 (±3) 11?25 
 Amp 2 0 100 10 (±2) 06?12 
 Amc 30 65 35 20 (±4) 11?31 
 Amc 3 0 100 11 (±2) 06?15 
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Table 16. Sensitivity and specificity values for four tests (disks) to detect BLNAR 
resistance in H. influenzae. Amp 10 = ampicillin 10 μg, Amp 2 = ampicillin 2 μg, Amc 30 = 
amoxicillin-clavulanic acid 30 μg, Amc 3 = amoxicillin-clavulanic acid 3 μg.  
Test (disk μg) N Sensitivity (%) Specifity (%) 
Amp 10 128 71 88 
Amp 2 129 92 90 
Amc 30 129 44 96 
Amc 3 129 91 87 
 
 
In addition to ampicillin and amoxicillin-clavulanic acid, the performance 
of the DD method for tetracycline and sulfamethoxazole-trimethoprim 
susceptibility testing was evaluated (unpublished). Zone diameter values 
provided by laboratories were combined (sulfamethoxazole-trimethoprim 
n=97, tetracycline n=84) to create a histogram.  The expected susceptibility 
distribution (S/I/R) for tetracycline was 30/0/60% and for 
sulfamethoxazole-trimethoprim 75/0/25% based on the information from 
UK NEQAS and ATCC (Fig.  17 and 18).   
 
    
      R 61%         I 6%   S 33% 
 
 
Fig.17. Distribution of inhibition zone diameters (mm) from 84 tetracycline disk (30 μg) 
diffusion tests. The vertical red lines indicate breakpoints defined by the NCCLS in 2004.  
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         R 23%         S 77% 
 
 
 
Fig.18. Distribution of inhibition zone diameters (mm) from 97 sulfamethoxazole-
trimethoprim disk (25 μg) diffusion tests. The vertical red lines indicate breakpoints 
defined by NCCLS in 2004.  
5.1.2 Macrolide resistance mechanisms in Haemophilus influenzae 
(unpublished)  
A total of 6 out of 713 isolates tested were identified as being resistant to at 
least one macrolide (Table 17). One isolate (Hi66) was resistant only to 
azithromycin and three isolates only to telithromycin (Hi98, 212 and 218). 
Two isolates (Hi286 and Hi593) had substantially higher MIC values for all 
antibiotics (>64 μg/ml) compared to the others. All strains showing 
resistance against the antimicrobial agents studied were collected in the 
1999?2000 period. No resistance was found in either an earlier 1990 or a 
later 2010 collection years. Telithromycin was not tested for the latest 
collection in 2000.  
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Table 17. MIC values and mutations in the macrolide binding site and altered amino acid 
sequences in ribosomal proteins  L4 and L22 among six H. influenzae isolates with 
decreased susceptibility to clarithromycin (Clr), azithromycin (Azm) and/or telithromycin 
(Tlt). 
 MIC values (μg/ml) a)                       Mutations  
Isolate Clr  Azm Tlt 23SrRNA b) L4c) L22c) 
       
Hi66 16 8 8    
Hi198 16 4 >32  T64K  
Hi212 32 8 >32  T64K  
Hi218 16 4 16  T64K  
Hi286 >256 >256 >256 A2058G   
Hi593 64 64 32   E78D, DEL79GP 
 
 
a) Interpretation criteria according to EUCAST breakpoints (μg/ml): clarithromycin >32 =resistant; 
azithromycin >4 = resistant; telithromycin >8 = resistant.  
b) E. coli numbering 
c) H. influenzae numbering 
 
None of the six resistant strains carried mef(A), erm(A), erm(TR), 
erm(B), erm(C) or erm(F) genes.  
No mutations in the domain V of 23S rRNA or ribosomal proteins and L4 
or L22 were detected in one isolate resistant only to azithromycin (Hi66, 
Table 14). Three isolates (Hi198, Hi212 and Hi218) showed modifications in 
the ribosomal protein L4 amino acid sequence. Threonine at position 64 was 
converted to lysine (T64K) in the L4 protein in all three strains and MIC 
values were elevated only for telithromycin. In all of these isolates, only one 
mutation known to confer macrolide resistance was detected in each. In one 
isolate (Hi286) adenine at position 2058 of 23S rRNA macrolide binding site 
was replaced with guanine (A2058G, E. coli numbering). In this isolate all 
MIC values exceeded 256 μg/ml. All six alleles of this particular H. influenzae 
isolate were mutated (Haanperä et al., 2005). This mutation was the only 
resistance mechanism associated with macrolide resistance that was found in 
this isolate.  
Only one strain (Hi593) carried a mutation in the gene encoding for the 
ribosomal protein L22. The six base-pair (bp) deletion from position 235 
forward, caused a replacement of glutamic acid by aspartic acid at position 
78 (amino acid position) and a loss of glycine and proline residues at 
positions 79 and 80 (E78D, DEL79GP, Fig. 19). The MIC values of this isolate 
were high for all antibiotics. No previously described mechanisms associated 
with macrolide resistance have been found for this isolate.  
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H. influenzae Rd KW20  
 
226   GTT GAT GAA GGT CCT AGC ATG AAA CGT GTT ATG CCA CGT GCT AAA   270 
76     V   D   E   G   P   S   M   K   R   V   M   P   R   A   K    90 
 
 
 
H. influenzae hi593  
 
226   GTT GAT GA- --- --T AGC ATG AAA CGT GTT ATG CCA CGT GCT AAA   270 
76     V   D   D   -   -   S   M   K   R   V   M   P   R   A   K    90  
Fig.19. Nucleotide and corresponding amino acid sequences of L22 riboproteins of H. 
influenzae Rd KW20 (wild-type) and Hi593. Bold letters indicate the nucleotide and 
amino acid changes in Hi593.  
5.2 Association between sulfamethoxazole-
trimethoprim use and resistance in Streptococcus 
pneumoniae, Haemophilus influenzae and Moraxella 
catarrhalis (II)  
We compared the regional use of the antibiotic to resistance in 21 central 
hospital districts in Finland to evaluate the effect of sulfamethoxazole-
trimethoprim use on resistance in S. pneumoniae, H. influenzae and M. 
catarrhalis. 
Annual, regional consumption figures for sulfamethoxazole-trimethoprim 
over the 1997–2003 period are shown in Fig. 20 and total consumption in 
Fig. 21. Consumption had declined in all health care districts until 2002, 
although not steadily. From 2002 up to the present the use of 
sulfamethoxazole-trimethoprim increased slightly for most regions, but the 
total use remained stable. Regional variation in the use of sulfamethoxazole-
trimethoprim was considerable (differences between highest annual use and 
lowest annual use varied from 0.43 to 0.70 DDD/1000 inhabitants/day).  
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Fig. 20. Regional sulfamethoxazole-trimethoprim consumption in 21 hospital districts in 
Finland on the 1997?2003 period.  
 
 
Fig. 21.Total consumption of sulfamethoxazole–trimethoprim in Finland on the 1997–
2003 period.  
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Resistance of S. pneumoniae, H. influenzae and M. catarrhalis to 
sulfamethoxazole–trimethoprim increased sharply from 1988 to 1999 (from 
4.5% to 21.4% for S. pneumoniae, from 2.7% to 18.1% H. influenzae and from 
0.2% to 11.4%, for M. catarrhalis) in Finland. Resistance started to decline 
for all three antibiotics after 1990 but started to rise again in 2003 except for 
M. catarrhalis (Fig. 22). In recent years, resistance in H. influenzae has 
increased up to 2014, but slightly declined in 2015. Among S. pneumoniae 
resistance is decreasing and resistance in M.catarrhalis –strains is still very 
low (FINRES, 2015).   
 
 
Fig. 22. Sulfamethoxazole–trimethoprim resistance (% resistant) in three respiratory 
pathogens over the 1988–2014 period. (Spn = S. pneumoniae, Hi = H. influenzae, Mc = 
M. catarrhalis). From 2007 resistance rates were not available (Nissinen et al., 1995, 
FINRES 1995–2015). 
For evaluating the association of consumption and resistance of 
sulfamethoxazole–trimethoprim in the three pathogens, we collected 
regional resistance data from the period 1998–2004. Altogether 23 530 
(annual variation 1928–4238) S. pneumoniae isolates, 28 320 (3043–5116) 
H. influenzae isolates and 14 138 (1818–2731) M. catarrhalis isolates were 
tested for sulfamethoxazole-trimethoprim during this period. No resistance 
data were produced from two (2/21) districts (Ahvenanmaa and Kainuu). 
The remaining 19 health care districts represent 98% of the whole Finnish 
population (http://www.kunnat.net/fi/).  
The statistical analyses indicated following associations between 
sulfamethoxazole–trimethoprim use and resistance: the regional 
consumption of sulfamethoxazole–trimethoprim seems to have an effect on 
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regional resistance among S. pneumoniae (p=0.007). The association was 
positive, which indicated that the greater the consumption 
sulfamethoxazole–trimethoprim, the higher was the resistance of S. 
pneumoniae in the following year. The change of resistance over time was 
not significant (p=0.452) however. The significance in change of resistance 
over time was borderline for H. influenzae (p=0.051) but consumption of 
sulfamethoxazole–trimethoprim failed to explain changes in the level of 
resistance (p=0.808). No significant change in sulfamethoxazole–
trimethoprim resistance was seen among M. catarrhalis (p=0.349) isolates, 
and again consumption failed to explain the level of resistance (p=0.744).  
 
5.3 Quality of resistance data in Finnish microbiology 
laboratories (III) 
 
A total of 21 out of 25 laboratories reported the internal quality control 
procedures from the three-year period of 2004 to 2006 inclusive. Of these 15 
(71%) included S. pneumoniae ATCC49619 in the internal quality control 
programme in 2004, 17 (81%) in 2005 and 16 (76%) in 2006. The 
corresponding figures for H. influenzae ATCC49247 were 14 (67%) in 2004, 
15 (71%) in 2005 and 14 (67%) laboratories in 2006, respectively. The 
procedures of individual laboratories are presented in Tables 18 A and B.  
The qc frequency of these two organisms varied by laboratory S. 
pneumoniae ATCC49619 was tested annually 0–81 times and H. influenzae 
ATCC49247 0–68 times in the laboratories that performed susceptibility 
testing for these species (Table 19). 
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Table 18 A. Antimicrobial agents tested against S. pneumoniae ATCC49619 in 21 Finnish 
laboratories using the disk diffusion and the E-test methods. 
Quality control 
limits approved 
(FiRe) 
Interpretive criteria 
established for 
clinical isolates (FiRe) 
Antimicrobial agent  Number of results 
(laboratories) 
  DD method (concentration of 
disk, μg) 
 
No No Ampicillin (10) 76 (1) 
No No Azithromycin (15) 64 (2) 
No No Cefaclor (30) 1 (1) 
No No Cephalotin (30) 329 (3) 
Yes Yes Chloramphenicol (30) 142 (4) 
No No Ceftriaxone (30) 150 (2) 
No No Cefuroxime (30) 2 (2) 
Yes Yes Clindamycin (2) 1607 (15) 
Yes Yes Erythromycin (15) 1773 (17) 
No No Levofloxacin (5) 329 (4) 
Yes Yes Oxacillin (1) 1412 (17) 
No No Meropenem (10) 98 (1) 
Yes Yes Moxifloxacin (5) 55 (2) 
No No Penicillin (10 IU) 837 (8) 
No No Rifampicin (5) 111 (2) 
No No Telithromycin (15) 113 (3) 
Yes Yes Tetracycline (30) 1248 (13) 
Yes Yes Sulfamethoxazole -trimethoprim (1.25) 
1582 (16) 
Yes Yes Vancomycin (30) 809 (10) 
    
  MIC (E-test)  
Yes Yes Ceftriaxone 99 (2) 
Yes Yes Cefuroxime 99 (1) 
Yes Yes Meropenem 98 (1) 
Yes Yes Penicillin 138 (4) 
 
Table 18 B. Antimicrobial agents tested against H. influenzae ATCC49247 in 21 Finnish 
laboratories using the disk diffusion method only. 
Quality control 
limits approved 
(FiRe) 
Interpretive criteria 
approved for clinical 
isolates (FiRe) 
Antimicrobial agent  Number of results 
(laboratories) 
  DD method (concentration of 
disk, μg) 
 
 No No Ampicillin (10) 382 (6) 
No Yes Ampicillin (2) 644 (12) 
No No Amoxicillin-clavulanic acid (20) 266 (5) 
No Yes Amoxicillin-clavulanic acid (2) 484 (9) 
Yes Yes Azithromycin (15) 1036 (13) 
No Yes Aztreonam (30) 97 (1) 
No No Cefaclor (30) 358 (6) 
No No Ceftriaxone (30) 201 (2) 
No No Cefuroxime (30) 318 (8) 
No No Doxycycline (30) 99 (2) 
No No Erythromycin (15) 89 (2) 
No No Imipenem (10) 97 (1) 
Yes Yes Tetracycline (30) 1159 (13) 
Yes Yes Sulfamethoxazole -
trimethoprim (1.25) 
1273 (16) 
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Table 19.  Annual frequency of quality control for S. pneumoniae ATCC49619 and H. 
influenzae ATCC49247 evaluation in 21 FiRe laboratories from 2004 to 2006  
 S. pneumoniae ATCC49619 H. influenzae ATCC49247 
       
Laboratory 2004 2005 2006 2004 2005  2006 
       
1 0 7 34 0 0 0 
2 44 48 55 32 35 27 
3 0 0 0 52 52 51 
4 9 23 29 4 7 10 
5 26 26 26 0 0 0 
6 0 2 21 0 2 40 
7 47 39 37 29 34 35 
8 40 37 36 30 34 35 
9 0 0 0 0 0 0 
10 91 70 82 68 62 57 
11 44 44 44 36 45 43 
12 13 14 23 13 14 24 
13 36 37 0 31 33 0 
14 0 0 0 0 0 0 
15 0 0 0 0 0 0 
16 88 33 33 15 15 18 
17 36 35 26 23 20 22 
18 52 50 47 0 0 0 
19 50 50 17 48 50 32 
20 18 24 28 16 24 24 
21 19 20 15 12 11 11 
 
 
A total of 19 different drugs/drug concentrations were included in the DD 
method quality control programme of S. pneumoniae ATCC49619. These 
included 11 antimicrobial agents or concentrations which were not included 
in the national guideline (ampicillin azithromycin, cefaclor, cephalotin, 
ceftriaxone, cefuroxime, levofloxacin, penicillin, rifampicin, telithromycin 
and meropenem). Of these 11 antimicrobial agents, eight (ampicillin, 
cefaclor, cephalotin, ceftriaxone, cefuroxime, penicillin, telithromycin and 
meropenem) are agents for which even the CLSI standard had not provided 
breakpoints at that time. Sixteen different drugs/drug concentrations were 
included in the DD quality control programmes of H. influenzae ATCC49247. 
This study also revealed that six drugs (cefaclor, ceftriaxone, cefuroxime, 
doxycycline, erythromycin and imipenem), which are not recommended in 
the national standard, were correspondingly tested for H. influenzae. Of 
these, two (doxycycline and erythromycin) were not included even in the 
CLSI breakpoint tables for H. influenzae during 2004 – 2006. In addition, 
six laboratories performed the ampicillin-test using 10 μg disks instead of 2 
μg disks, and they also conducted the amoxicillin-clavulanic acid test using 
the 20 μg disks instead of 3 μg disks. These procedures were contrary to the 
recommendations laid down by the FiRe Group.  
The susceptibility testing results of S. pneumoniae ATCC49619, which 
used the MH medium (supplemented with 5% defibrinated horse blood) 
showed good reproducibility. Between 86 and 99% (depending on the 
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antimicrobial agent) of test results fell within the defined qc-limits provided 
for the DD method. Laboratories that used IsoSensitest (IS) agar with horse 
blood performed worse in this analysis (only between 45 to 82% of results 
were within qc-limits). The numbers for MIC-values were fairly small, and no 
clear differences between the two media can be seen. The reproducibility of 
H. influenzae testing using HTM agar was very high with tetracycline (95% 
within limits) and sulfamethoxazole-trimethoprim (90% within limits), but 
with azithromycin nearly 30% of results fell outside the qc-limits.  The lack of 
confirmed qc-limits for H. influenzae ATCC49247 with low-potency 
ampicillin and amoxicillin-clavulanic acid disks indicated that their 
performance could not be compared to the established criteria. However, 
calculating the 2.5 and 97.5 percentiles of their inhibition zones provided a 
range that would cover 95% of observations (BSAC, 2013), thus the   qc-
limits for ampicillin 2 μg would be imputed to fall into the range of 6–15 mm 
and the corresponding qc-limits for amoxicillin-clavulanic 3 μg the limits to 
be 8–17 mm. 
Besides the reproducibility, the categorical validity (S/I/R) of the qc-
results was calculated. Reduced susceptibility of S. pneumoniae ATCC49619 
(NS=not susceptible) was detected as expected with the oxacillin-screening 
test and also with the E-test method. Moreover, the interpretations for the 
other antimicrobial agents were nearly correct and no clear differences could 
be seen between the two media used (Table 20). The reduced susceptibility to 
ampicillin (due to altered PBP) in H. influenzae ATCC49247 was better 
detected by using the low concentration ampicillin and/or amoxicillin-
clavulanate disks. For other antimicrobials the interpretations were nearly as 
expected (Table 21). 
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Table 20. Categorical accuracy of the internal quality control results of S. pneumoniae 
ATCC49619 using the DD or E-test method (MIC). Results of two different media are 
presented separately.  R=resistant, I = intermediate, NS = non-susceptible, 
S=susceptible.  
Method1) n R (%) I (%) NS (%) S (%) 
      
Oxa disk MH 950   99.7 0.3 
Oxa disk IS 439   99.5 0.5 
Pen MIC MH 62 0 100  0 
Pen MIC IS 76 0 98.7  1.3 
Tcy disk MH 938 0 0  100 
Tcy disk IS 290 0 0.3  99.7 
Cli disk MH 1051 0 0  100 
Cli disk IS 533 0 0  100 
SxT disk MH 1137 0.4 1  98.6 
SxT disk IS 424 1.7 3.1  95.3 
Ery disk MH 1142 0 0  100 
Ery disk IS 608 0 0  100 
Van disk MH 384 0 0  100 
Van disk IS 405 0 0  100 
 
1) Oxa = oxacillin, Pen. = penicillin, Tcy = tetracycline, Cli = clindamycin, SxT = sulfamethoxazole-trimethoprim, Ery = 
erythromycin, Van = vancomycin; MH refers to Mueller-Hinton medium, IS refers to Isosensitest-medium. 
Breakpoints as defined in the CLSI-standard and/or the FiRe-guideline.  The expected results are highlighted in 
bold lettering.  
 
Table 21. Accuracy of the internal quality control results of H. influenzae ATCC49247 in 
laboratories using HTM–medium and DD method.  R=resistant, I = intermediate, NS = 
non-susceptible, S=susceptible.  
 
Method1) n R (%) I (%) NS (%) S (%) 
      
Amp 2 disk 596 93.1 5.4  1.5 
Amp 10 disk 372 20.2 57  22.8 
Amc 3 disk 484 79.5 15.9  4.5 
Amc 30 disk 218 21.1 0  78.9 
Azm disk 1023 0 0  100 
Tcy disk 1099 95.9 3.3  0.8 
SxT disk 1255 0.1 0  99.9 
 
1) Amp = ampicillin, Amc = amoxicillin-clavulanic acid, Azm = azithromycin, Tcy = tetracycline, SxT = 
sulfamethoxazole-trimethoprim. Breakpoints as defined in the CLSI-standard and/ or the FiRe-guidelines. The 
expected results are highlighted by bold lettering.  
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5.4 Susceptibility testing of Streptococcus pneumoniae 
with the E-test and the Vitek2- AST-GP74 test (IV) 
 
Time to results (TTR) of susceptibility testing with the VITEK2® system 
ranged from 8.5 to 17.5 hours (mean 10 hours , average 10.8 hours) Only one 
(1/230, 0.4%) isolate was discarded from the study due to insufficient 
growth.  
The CA and FS rates for the VITEK system and E-test are shown in Table 
21. Breakpoints for non-meningitis S. pneumoniae EUCAST (EUCAST 2016) 
were used for categorization. Both methods correlated well with the reference 
method with 98.2% (Vitek2® AST-GP74) and 97.3% (E-test) agreement in 
S/I/R categories. The lowest CA value was obtained for sulfamethoxazole-
trimethoprim by the E-test (88.2%). Numbers of FS results were very low 
(1% and 1.3%) with both methods. 
Total error rates with non-meningitis breakpoints (mE, ME, VME) for the 
Vitek AST-GP74 were low (1.3, 0.1 and 1.6%). The E-test provided 
correspondingly 2.2, 0.1 and 4.9% errors. With meningitis breakpoints, the 
error rates were 0.2, 0.0 and 2.6% for the Vitek2 and 0.7, 0.0 and 0.0% for 
the E-test.  
Total EA for the Vitek2 AST-GP74 was 99.1% and 89.1 % for the E-test.  
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Table 21.  Performance of Vitek2 AST-GP74 and the E-test compared to the broth dilution 
results for 229 S. pneumoniae-isolates. CA = categorical agreement, FS = false susceptible.  
Vitek AST-GP74 E-test 
  CA FS CA FS 
  fraction n % 
fractio
n n % 
fractio
n n % 
fractio
n n % 
Penicillin 219 229 95.6 2 229 0.9 221 229 96.5 0 229 0.0 
        
Cefotaxime 221 229 96.5 3 229 1.3 219 229 95.6 9 229 3.9 
        
Ceftriaxone 218 229 95.2 9 229 3.9 220 229 96.1 1 229 0.4 
        
Meropenem 228 229 99.6 0 229 0 229 229 
100.
0 0 229 0.0 
        
Moxifloxacin 228 229 99.6 1 229 0.4 228 229 99.6 1 229 0.4 
        
Levofloxacin 229 229 
100.
0 0 229 0 ND ND ND ND ND ND 
        
Erythromycin 228 229 99.6 1 229 0.4 229 229 
100.
0 0 229 0.0 
        
Tetracycline 228 229 99.6 1 229 0.4 226 229 98.7 0 229 0.0 
        
Sulfamethoxazole
-trimethoprim 220 229 96.1 7 229 3 202 229 88.2 13 229 5.7 
        
Vancomycin 229 229 
100.
0 0 229 0 229 229 
100.
0 0 229 0.0 
        
Linezolid 229 229 
100.
0 0 229 0 ND ND ND ND ND ND 
        
Total  2477 2519 98.3 24 2519 1.0 1782 1832 97.2 24 1832 1.3 
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6 DISCUSSION 
6.1 General discussion 
 
This thesis describes the development, evaluation and quality of 
susceptibility testing methods with particular emphasis and reference to the 
important respiratory tract pathogens S. pneumoniae and H. influenzae.  
Methodological harmonization has proceeded well in Finland due to the 
activities of the FiRe network. Thanks to this network, a continually 
increasing comprehensive and uniform body of resistance data of bacterial 
pathogens exists and it now covers more than two decades. These data were 
and are used to model the association between antimicrobial use and 
resistance in these respiratory pathogens and M. catarrhalis. A point 
prevalence study in 2001 indicated that the respiratory tract infections are 
the most common infections treated in health care centers (74%). 
Antimicrobial treatment was prescribed for 88% of patients with otitis 
media, 83% with sinusitis and 71% with acute bronchitis (Rautakorpi et al., 
2001). These figures highlight the importance of antimicrobial research on 
respiratory bacteria.  
The degree of antimicrobial resistance among human pathogens has 
hitherto been low or moderate in Finland. Currently, rising trends are 
apparent, however, especially in the case of pneumococci (ECDC, 2015 a). 
One aim of the FiRe network is to maintain resistance of pathogens to 
antiobiotics at low level by guiding the use of antibiotics with the help of 
limited, but still appropriate and valid susceptibility results. This is done in 
cooperation with infection diseases specialists.  
From the beginning of 2011, Finnish laboratories, like many other 
European laboratories, have implemented the EUCAST method (EUCAST, 
2016) for susceptibility testing of bacteria and this has superceded the 
national FiRe standard. This switch in guidelines entailed some 
methodological and interpretative changes. The basic susceptibility testing 
procedure is still the DD method in most laboratories, although the number 
of laboratories that use automated methods is increasing. EUCAST has 
proceeded well in harmonising methods and breakpoints for antimicrobial 
susceptibility testing of bacteria since 2010, when the first version for disk 
diffusion method was launched. EUCAST breakpoints are also available for 
automated susceptibility testing devices with some limitations depending on 
the system. European countries have widely adopted the EUCAST method 
and its breakpoints as nearly 90% of laboratories that participate in 
UKNEQAS distributions in 2014, use EUCAST (ECDC, 2015 a). The results of 
this study are also highly applicable for current testing standards and 
practices. 
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6.2 Evaluation of the data  
We evaluated the susceptibility testing method of H. influenzae resistance for 
the FiRe standard (I), whereby 26 laboratories performed testing and 
reported results. This covers nearly 100% of Finnish clinical microbiology 
laboratories. Hence, 128–129 repeated tests/disks were received for this 
study. We used five strains that were obtained from type-strain collections 
(ATCC) and the UKNEQAS quality control distributions to carry out this 
evaluation. Unfortunately, the information concerning the altered penicillin 
binding proteins associated with the BLNAR type of resistance and the 
genetic confirmation for tetracycline (isolates 1, 3 and 5) or 
sulfamethoxazole-trimethoprim resistance (isolate 1) were only available for 
one isolate from ATCC or UKNEQAS databases.  
Resistance data used in study II were collected from the annual, 
nationwide surveillance, FINRES. The material covered data for seven years. 
Each laboratory provided information on the total number of strains it 
examined and the numbers of susceptible, intermediate and resistant strains 
it found. The resistance data are based on the routine susceptibility testing 
over the whole year for each laboratory and includes all consecutive isolates 
regardless the site of infection. Multiple isolates of a patient could not be 
excluded from these datasets. Usually there is only one or two large 
microbiological laboratories in each hospital district. It has been estimated 
that more than 90% of bacteriological specimens in a health care district are 
examined in these “central” laboratories. This is especially true of the 
laboratories in the public health care sector. Additionally, we had four private 
laboratories that provided services mainly for private clinics and 
occupational health care at the time of the study. These four laboratories also 
provided resistance data to the FINRES surveillance. Geographically the data 
from private laboratories may be more heterogeneous than the data from 
public health care laboratories.  The location of the laboratory was used as a 
geographical indicator in this study.  Some smaller private laboratories all 
over Finland do not provide resistance data for the FINRES report. The 
impact of not having the information of the small laboratories on these 
FINRES data would be neglible, however. An exact figure of the 
completeness of the resistance data is not possible, but the population in the 
health care districts, where the resistance data were available represent about 
98% of the total population in Finland. We included the resistance rates 
based on at least 30 tested isolates per year for statistical reasons; one may 
assume that the resistance rates among small numbers of tested isolates may 
be biased. Hence, one can state that the resistance data used is quite uniform 
and has a good coverage.   
Antimicrobial consumption information is collected in Finland as 
DDD/1000/inhabitants/day (Fimea). In the present study (II) the sum of the 
quantities of sulfamethoxazole-trimethoprim sold from the two biggest 
wholesalers to pharmacies was used. Consumption figures from all 21 central 
 92 
hospital districts were available and hence these consumption data covered 
the whole country. Hospitals do purchase medicines from other wholesalers 
and directly from pharmaceutical companies and they may even import 
drugs directly from abroad. These quantities are estimated to represent, 
however, only 1% of the total sales of all medicines. In the case of 
antimicrobial agents this figure has been estimated to be even smaller. 
Accordingly, the consumption figures used in this study cover at least 99% of 
the actual sales. There are some conflicting factors that cannot be excluded, 
such as the quantities derived from unused prescriptions. Additionally, we 
have no guarantees, that a prescription purchased in one health care district 
is consumed in the same area.  It was mentioned in the Review of literature 
of this thesis and also pointed out in a review by Fortin et al. (2014), that no 
single measure gives a complete picture of antimicrobial use. For instance, 
prescriptions for children are based on weight; this fact is not taken into 
account when the DDD measure is used. 
The quality of the resistance data was evaluated by means of test results 
for two qc-isolates, H. influenzae ATCC49247 and S. pneumoniae 
ATCC49619 (III). Consecutive results were collected from the FiRe 
laboratories. These two isolates were the concurrently recommended qc-
strains for the FiRe standard. Both strains possess “difficult to detect” 
resistance traits (Tenover et al., 2001, Snell, 1994; Manninen et al., 1998 a, b) 
and thus offer a good perspective to survey the competence of 
microbiological laboratories at the national level.  
The S. pneumoniae isolates used in study IV represent consecutive 
clinical blood culture isolates (non-selective) and a set of miscellaneous 
pneumococcal isolates, chosen for decreased susceptibility for penicillin in 
the initial AST. The number of isolates was 229 and they were collected from 
one laboratory. According to the FDA guidelines (FDA, 2009) an ideal 
distribution for methodological evaluations would be 100 isolates of which 
50% are susceptible and 50% resistant-strains. However, this kind of 
distribution may be difficult to collect in practice, especially when resistance 
is not common. The distributions of S/R isolates expressed as percentages 
varied in our dataset from 100/0–66.8/33.2% (Table 12). It would be 
practically impossible to collect 50% resistant strains to all antimicrobial 
agents tested from the whole country. Repeat isolates from same patient 
were excluded in case they were obtained less than two months apart.  
H. influenzae isolates for searching macrolide resistance mechanisms 
(unpublished) were obtained from periods in three decades and represent 
isolates before and after azithromycin and ketolide were introduced. The 
earliest collection (1988?1991) was selective with regard to specimen site and 
the age of the patient. The collection from the 1999?2001 period includes 
isolates from non-selective specimens and all age groups. The latest subset 
(2006?2011) represents partly selective isolates from children with suspected 
otitis. Differences in age, infection site and geographical distribution may 
thus create bias in the results.  
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6.3 Antimicrobial susceptibility testing methods, 
changes in international standards and quality of 
results (I, III, IV) 
6.3.1 Haemophilus influenzae 
6.3.1.1 BLNAR 
The detection of non-β-lactamase mediated ampicillin resistance is perhaps 
the most difficult components of the susceptibility testing of H. influenzae. 
This resistance mechanism has already surpassed β-lactamase mediated 
resistance in the eastern hemisphere (Ubukata et al., 2003, Witherden et al., 
2011, and Park et al., 2013). These BLNAR isolates are also ascending in 
Europe and North America (Skaare et al., 2014; Shuel et al., 2011). In Finland 
BLNAR isolates have been found occasionally so far. Consumption of 
cephalosporins in the 1990s was relatively high in Finland compared to other 
Nordic countries (Bergan, 2001). The first-generation cephalosporins in 
particular were used clearly more in Finland than in other European 
countries in 2009 regardless of the measure used (DID or PID) (Versporten 
et al., 2011). The high use of cephalosporins in Japan has been associated 
with elevated BLNAR prevalence for H. influenzae (Hasegawa et al., 2006). 
For these reasons it is important to detect and follow this resistance in 
Finnish H. influenzae isolates.  
  I have shown in this thesis, that the use of low-concentration disks of 
ampicillin and amoxicillin-clavulanic acid in susceptibility testing compared 
to the high-concentration disks that had previously been used, improves the 
DD method. This was shown with challenge strains in an inter-laboratory 
study (I) and also in the quality control results of Finnish microbiology 
laboratories (III). These results are comparable with the findings reported by 
Zerva and co-workers (1996) and by Sondergaard et al. (2012). As a 
consequence, the low-concentration disks with HTM medium were adopted 
for the DD method in the national FiRe standard in 2002. The breakpoints 
were set at ≤13 mm (R) and ≥17 mm (S) for both disks. The suggested quality 
control strain was H. influenzae ATCC49247 (BLNAR).  
Most laboratories in Finland switched from the FiRe standard to EUCAST 
from the beginning of 2011 and changes were made for AST of H. influenzae. 
The EUCAST method utilises MH-F medium instead of the formely used 
HTM. The use of a low concentration ampicillin disk (2 μg) but high 
concentration amoxicillin-clavulanic acid disk (30 μg) was the method of 
choice in the first EUCAST guideline versions (1?1.3). Version 2.0 (published 
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1.1.2012) stipulated a low concentration amoxicillin-clavulanic disk (2+1 μg) 
to replace the high concentration disk previously used and a novel screening 
method to detect ampicillin resistance (penicillin disk, 1 unit) was 
introduced. These changes were shown to have best sensitivity and accuracy 
in identifying H. influenzae strains with PBP3 mutations. This method was 
not suitable for ampicillin resistant, β-lactamase positive (BLPAR) isolates, 
however, and therefore a cefuroxime (5 μg) disk was suggested instead 
(Skaare et al., 2015). That study also included a warning about ignoring a 
hazy growth within inhibition zones.  
The CLSI guideline still relies upon high-concentration ampicillin and 
amoxicillin-clavulanic acid disks and HTM medium in AST of H. influenzae 
(CLSI, 2015). The benefit of using the HTM medium is a more distinct 
endpoint compared to more nutrient-rich media such as MH-F (Barry et al., 
2001).  
The tetracycline results in our study indicate that a part of the susceptible 
population was misclassified as belonging to the intermediate category. The 
sulfamethoxazole-trimethoprim tests, however, showed good accuracy. The 
histogram is clearly bi-modal and the existing breakpoints do not split the 
susceptible and resistant populations (Unpublished, Fig. 17 and 18). 
Switching from the FiRe standard to EUCAST in 2011 has not changed the 
observed resistance rates of ampicillin, amoxicillin-clavulanate and 
tetracycline in H. influenzae in Finland. The observed sulfamethoxazole-
trimethoprim resistance instead is higher for all age groups in the EUCAST 
era.  Resistance was from 18.1% in 2008 to 21.9% in 2010 (during the pre-
EUCAST era) and has varied between 23.6 and 31.2% in the EUCAST era 
(FINRES, 2015). However, there is no direct evidence to suggest that the 
observed rise in resistance is a consequence of methodological changes or 
different breakpoints following the implementation of EUCAST.   
6.3.1.2 Macrolides 
We examined 713 H. influenzae-isolates from periods belonging to three 
different decades that had been submitted by various laboratories in Finland. 
Only 6 out of 713 (0.8%) strains were resistant for one or more macrolides 
according to the CLSI breakpoints or current EUCAST breakpoints. The 
breakpoints used today have been set basically to differentiate wild-type 
strains, and not for the classification of H. influenzae into susceptible, 
intermediate or resistant types. The correlation between macrolide MIC 
values of H. influenzae and clinical outcome is poor due to intrinsic efflux 
possessed by most H. influenzae strains (Peric et al., 2003; Bogdanovich et 
al., 2006). Despite the poor correlation it would be of interest to examine, 
whether the well-known resistance mechanisms in other bacteria that share 
the same habitat have spread to H. influenzae.  
We found no mobile macrolide resistance genes in our isolates. This 
finding agrees with the results obtained by Peric et al. (2003) from the 
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Alexander-project (Felmingham et al., 2005; Atkinson et al., 2015) from 
Australia. On the other hand, Roberts and colleagues in 2011 and in 2015 
found the mobile erm and mef genes in H. influenzae isolates in North-
America among children with CF (Roberts et al., 2011; Roberts et al., 2015).  
50% of patients were exposed to azithromycin during the study and 
presumably all children had a previous history of macrolide therapy. Our 
material is non-selective with regard to patients’ previous exposures to 
macrolides, which is a similar condition that prevailed in the study by Peric 
and co-workers.  In the Australian study, however, 15.7% of patients were 
known to have had a significant macrolide exposure prior to culture of H. 
influenzae. In total resistance rates were low (< 5 %) in that study except of 
those isolates with preceeding exposure, where it was 25.5%. It is likely, that 
among selective populations (with preceding exposure), horizontal transfer 
of macrolide resistance in H. influenzae may occur. However, among 
populations without such burden this is not a probable perspective. This 
conclusion endorses avoiding heavy use of macrolides in the treatment of 
community acquired infections. CF is a rare disease in the Finnish 
population (Halme et al., 2006); hence patients with long azithromycin 
therapy are infrequent.  
Four different mutations were detected in the Finnish macrolide resistant H. 
influenzae isolates. The transversion of adenine to guanine in position 2058 
of 23SrRNA (A2058G) has been reported earlier in other respiratory bacteria 
and H. influenzae (Jalava et al., 2004; Pihlajamäki et al., 2002; Peric et al., 
2003). We found this mutation in one isolate (hi239), which showed high 
resistance to all macrolides, including telithromycin. In pneumococcal 
isolates telithromycin has remained active, when this mutation is present 
(Farrell et al., 2003; Van Eldere at al., 2005).  Three isolates carried 
previously described (Peric et al. 2003) mutations in the L4 ribosomal 
protein, which led to the one amino acid substitution (threonine to lysine at 
position 64). All of these strains were resistant to telithromycin and one 
strain was resistant to azithromycin as well. Finally, we found a novel 
mutation in the ribosomal protein L22, which was associated with high level 
resistance to all macrolides. The six base pair loss caused one amino acid 
substitution and loss of two amino acids in the highly conservative region of 
the L22-protein (E78D, DEL79GP). No other previously described resistance 
mechanisms were detected and therefore this mutation is likely to be the 
molecular mechanism behind macrolide resistance in this particular isolate. 
6.3.2 Streptococcus pneumoniae 
A high level of agreement between an automated susceptibility test-system 
(VITEK2® AST P74-card) and the BD method (Sensititre®) was found in this 
study. All calculated parameters: CA, EA and number of errors were within 
limits, which the FDA (2009) has defined for approval of a novel 
susceptibility testing system with the non-meningitis breakpoints set by 
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EUCAST. The FSR rate was very low, as well. The FDA specifications are not, 
however, fully applicable to this study, because the bacterial population did 
not meet the ideal distribution (50% susceptible, 50% resistant). It is stated 
in the FDA document, however, that this may be a rare situation when 
consecutive clinical isolates are used. It is also worth noting that, several 
reports around the world indicate that resistance to vancomycin and linezolid 
does not occur among pneumococci. 
Automatic susceptibility testing methods are used by many 
microbiological laboratories, mostly for gram-negative rods and 
staphylococci. When these fully automated systems have been evaluated, 
problems have been observed with S. pneumoniae. The discrepancies have 
been mostly classified as minor errors in many evaluations (Ligozzi et al., 
2002; Chavez et al., 2002; Goessens et al., 2000; Abele-Horn et al., 2006). A 
cross-comparative study conducted by Mittman and co-workers (2009), 
reported that the Phoenix® system produced fewer VMEs  (n=1) than the 
VITEK2®-system (n=7) among 311 isolates tested. CA, EA and ME were, 
however, very similar between both methods and thus met the minimum 
requirements of the FDA (2009). The difference in the number of VMEs 
might be a reflection of a shorter TTR of the VITEK2®-system (average 9.8 
hours) compared to that of the Phoenix® -system (average 12.1 hours). The 
BD method was used as a reference for the MIC values.  
The high VME number (2.6%) for penicillin with the meningitis 
breakpoints is of concern regarding the Vitek2 method. This in agreement 
with the work of Charles and co-workers (2016), who compared four 
commercial methods and showed that with CLSI breakpoints for the E-test, 
M.I.C.E (MIC Evaluator®) and VITEK2® provided unacceptable error rates, 
especially with the meningitis-breakpoints. In addition, these methods 
tended to report lower MIC values for β-lactams than that obtained by the 
reference BD method.  
The aim of this study was to validate an automated method to replace the 
standardized DD method for S. pneumoniae. This would promote the 
automatization in clinical microbiology laboratories. These results indicate 
that the VITEK2®-AST-GP74 is a decent option for this purpose. However, 
the isolates from cerebrospinal fluid samples must be tested by other 
methods. The utilization of rapid laboratory technology with positive blood 
cultures reduces the use of broad-spectrum antibiotics and treatment of 
contaminants especially, when rapid identification of the pathogen is 
combined with antimicrobial stewardship (Banerjee et al., 2014; Sothoron et 
al., 2015).  
6.3.3 Quality assurance 
Assessment of laboratory performance in susceptibility testing is important 
for two reasons: 1. the results have direct influence on patient care 2. reliable 
data are needed for surveillance studies of antimicrobial resistance. Good 
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laboratory practices call for laboratories to participate in external quality 
assurance schemes (EQA) and monitor all susceptibility testing methods they 
use by defined internal qc-programs (IQA).  
We examined the IQA results of Finnish laboratories to get a picture of 
the national FINRES data of S. pneumoniae and H. influenzae. The study 
was conducted in the 2004–2006 period, i.e. the FiRe standard era. Two 
findings were unexpected. First, 3 out of 21 laboratories in study period did 
not include the recommended pneumococcal quality control strain in the 
IQA programme and 4 out of 21 laboratories did not use the recommended 
H. influenzae strain. However, all these laboratories produced susceptibility 
results for clinical S. pneumoniae and H. influenzae isolates. Second, some of 
the laboratories that participated in this study, tested and reported results for 
antimicrobial agents without defined breakpoints for clinical isolates or 
ranges and targets for the specified qc-strain. This practice has been reported 
earlier in the USA (Doern et al., 1999). Moreover, eight out of 21 laboratories 
in our study that tested penicillin susceptibility of S. pneumoniae used the 
high-strength 10 μg penicillin disk and a few laboratories tested ceftriaxone, 
cefuroxime and meropenem susceptibility with the DD method. Additionally, 
only a few laboratories monitored the results of the MIC methods for S. 
pneumoniae although they examined the isolates obtained from invasive 
infections. ‘Non-compliant’ disks of ampicillin 10 μg and amoxicillin-
clavulanic acid 30 μg were also used for H. influenzae. Erythromycin was 
also tested in two of the 21 laboratories, although its activity against H. 
influenzae is low. Additionally, ceftriaxone and cefuroxime were tested with 
the DD method. However, one can estimate from the data collected, that 
>90% of the national surveillance data was produced with methods with high 
compliance with the national guidelines.  
The present study of the IQA results in Finnish laboratories confirms the 
earlier finding (I), that non-β-lactamase mediated chromosomal ampicillin 
resistance in H. influenzae is detected with better accuracy, when low 
concentration of ampicillin (2 μg) and/or of amoxicillin-clavulanic acid (3 
μg) disks are used in the DDD method. Several wild type quality control 
strains (ATCC9334 and NCTC 8468) have been recommended in previous 
versions of the EUCAST standard for H. influenzae testing. The current qc-
isolate is ATCC49766. The extended qc recommendation includes an isolate 
with the PBP3 mutation, ATCC49247 (EUCAST 2016). This β-lactam 
resistant isolate is included in the CLSI as a regular control (CLSI 2015). In 
view of our results (III) the inclusion of one BLNAR qc-strain along with the 
wild-type strain is useful to confirm the capacity of laboratories to find the 
difficult-to-detect, and possibly emerging ampicillin resistance in H. 
influenzae. So far, no qc-data are available on the capacity of penicillin disks 
in routine laboratory work in Finnish laboratories to detect correctly the 
isolates with altered PBB3 proteins, although this has been well documented 
elsewhere (Skaare et al., 2015).  
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S. pneumoniae ATCC49619 is the recommended qc-strain for both 
prevailing AST standards (EUCAST and CLSI). There is a paucity of data on 
the effect of medium to susceptibility results among pneumococci.  A study 
by Jones and colleagues (1996), however, observed that the choice of 
susceptibility test medium (Iso-Sentitest/Muller-Hinton) affected the 
expression of macrolide-lincosamin-streptogramin (MLS) resistance in S. 
pneumoniae.  
The assessment of laboratory performance should be studied anew with 
current practices. However, as mentioned earlier, the primary H.  influenzae 
qc-strain is different from that used in this study and it has also been altered 
during the EUCAST era. Therefore, there is probably not enough data of this 
aspect to make any firm conclusions about the present state.  
6.3.4 Association  between antimicrobial resistance and 
consumption (II)  
The sulfamethoxazole-trimethoprim resistance fluctuated in Finland among 
the major respiratory tract pathogens in our study period 1998–2004. A 
remarkable decline in resistance is seen among pneumococci since 2010. The 
number of multiresistant isolates has also declined. Resistance has risen 
among H. influenzae in all age groups and been quite persistent among M. 
catarrhalis during the same period (FINRES, 2015).  
A statistically significant association between sulfamethoxazole-
trimethoprim consumption and resistance in S. pneumoniae was shown in 
this study but not among other respiratory pathogens (II). The trend in 
sulfamethoxazole-trimethoprim consumption, and that of trimethoprim 
(Tmp) alone, are declining (www.fimea.fi). When the current resistance 
figures are examined, one has to bear in mind, that the transition to the 
EUCAST method in Finnish laboratories may have influenced the resistance 
rates since 2011 due to the methodological changes and different breakpoints 
that followed the implementation.  
The effect of changes in antimicrobial use on resistance is a complex 
issue. As discussed in the Review of literature section (2.4.1.), several studies 
have shown a positive connection between antimicrobial use and resistance. 
On the other hand, there are studies that show no association or even a 
negative association. Clonal spread of resistant strains is probably one reason 
to explain persistent resistance despite a restriction in antimicrobial use 
(Arason et al., 2002). We do not have genotypic information of the isolates 
used in this study. Hence, we do not know, whether the spread, persistence 
or disappearance of resistant clones has affected the results. Statistical data 
of resistance was the method of choice in this study instead of a subset of 
bacterial strains. With this approach we were able to collect the data from a 
fairly long time span and from a wide geographical area. We also lack 
information of multiresistance among the bacterial strains used in this study. 
Multiresistance is relatively common especially among pneumococci in 
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Finland (3.0% for four antimicrobial agents and 7.4% for two antimicrobial 
agents in 2015) and in Europe as a whole (FINRES 2015, ECDC 2015a). Dual 
resistance was associated with serogroups 19, 14 and 6 in 12 European 
countries.  
Multiresistance may be one reason to explain the persistence or increase 
in resistance despite declining consumption of one antimicrobial agent. 
There is no recent data of multiresistance among H. influenzae, so 
conclusions of its persistent or rising resistance to sulfamethoxazole-
trimethoprim cannot be evaluated from this point of view. The lack of 
clonality among multiresistant H. influenzae, in the 1990s was shown in two 
studies (Fuste et al., 1996; Gazagne et al., 1998).  
Sulfonamide resistance in E. coli has remained at the same level in the UK 
despite a 97% reduction in its consumption. Several factors may have 
contributed to the persistence of resistance, such as the use of sulfonamides 
in veterinary medicine or the co-selection of sulfonamides-resistance by 
other antimicrobial agents. An interesting result reported by Enne et al. 
(2004) is that not all plasmids that conferred sulfonamide resistance reduced 
the fitnes of the host cell. Indeed, they found a plasmid, p9123, which 
actually improved it. 
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7 CONCLUSIONS AND FUTURE 
CONSIDERATIONS 
The key findings of the present study are : 
(1) The detection of H. influenzae bacterial strains that carry 
mutations in the PBP 3-proteins (BLNAR-type resistance) is more accurate 
with the DD method when low-strength ampicillin (2 μg) and amoxicillin—
clavulanate (3 μg ) disks (I, III) are used instead of the coresponding high-
concentation disks (10 and 30 μg ) (sensitivities 92 and 91% for low-strength 
compared to  71 and 41% for high-strength). This resistance is of importance, 
because these drugs are the first line treatment of acute otitis media in 
children and other upper respiratory tract infections. Globally this type of 
resistance has increased and is often suggested to be a consequence of the 
high use of cephalosporins. In Finland, cephalosporins are among the three 
most prescribed antimicrobial agents in outpatient care. This highlights the 
necessity to use best practices in the β-lactam susceptibility testing of H. 
influenzae.  
(2) Regional changes in sulfamethoxazole?trimethoprin consumption 
were shown to have a positive association with regional resistance rates 
among S. pneumoniae but not among H. influenzae and M. catarrhalis (II). 
Changes in resistance were not significant over time in the study period of 
seven years. Genetic analyses of representative subsets of these bacteria are 
needed to find the mechanisms for these observations Studies on the link 
between antimicrobial use and resistance of bacteria are also needed to find 
which agents cause the least resistance pressure among pathogenic bacteria. 
Many studies show a link between antimicrobial use and resistance for 
different population levels. An intresting point of view would be to study this 
association at the individual level.  
(3) Analysis of quality control results with susceptibility testing in 
Finnish microbiology laboratories showed that by using standardised 
methods, the results are highly reproducible. Two quality control strains, H. 
influenzae and S. pneumoniae with challenging, but important resistance 
traits, were correctly detected with excellent cover. However, noncompliance 
with the standardised methods was seen in many laboratories. A 
corresponding analysis of susceptibility testing in the EUCAST era would also 
be useful.  
(4) The automated susceptibility testing method (VITEK2®) may offer 
an alternative for the testing of S. pneumoniae in clinical laboratories. The 
obvious benefit would be that results would be obtained much faster than the 
current conventional manual methods (time to results a mean of 10 hrs 
compared to 18–24 hrs for manual methods). However, the discrepant 
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results for antimicrobial agents used for the treatment of meningitis, 
obtained by this method are of note and caution is required in adopting new 
methods. 
(5) Wild type H. influenzae with respect to macrolides, azalides and 
ketolides, have dominated in Finland up to 2011, at least among children. A 
very small number of resistant strains were found, and none of them carried 
the genes mobile resistance genes (mef and erm) found in other bacterial 
species. However, three types of mutations in the V domain of 23SrRNA and 
ribosomal proteins L4 and L22 were detected. The lack of mobile genes 
conferring resistance is likely due to fairly low and steady consumption of 
these antibiotics in Finland. 
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